AI Cloud Drives an Earnings Step Change; BOCI Initiates Envision Greenwise (01783) at BUY

EQS via SeaPRwire.com / 16/10/2026 / 11:15 UTC+8 Zhitong Finance App has learned that BOCI Securities has published an initiation report on Envision Greenwise (01783), assigning a BUY rating and a target price of HK$6.90. The report values the company on 20x FY2029E EPS (EPS of approximately HK$0.34) and believes AI Cloud will become the company's principal earnings growth engine, transforming its earnings mix. AI Cloud Becomes the Core Earnings Engine The report notes that in June 2026 the company announced the acquisition of interests in YV CLOUD and Shanghai Yovole Cloud Computing for a base consideration of HK$2.2bn, entering cloud computing and AI infrastructure services. It then advanced purchases of high-performance servers for its AI Cloud business, kicking off the transformation into a compliant AI computing platform. Scarcity of computing capacity is the core of the industry's thesis. Against the backdrop of US export controls, the company has gained access to scarce, compliant NVIDIA server procurement channels for China through the NVIDIA Cloud Partner (NCP) credentials held by Shanghai Yovole. According to BOCI's channel research, the company had secured an initial allocation of over 500 high-performance eight-GPU servers, equivalent to more than 4,000 GPUs, while customer orders substantially exceed the company's existing GPU capacity. Domestic high-end computing rents remain firm. Mysteel data show that H100 on-demand rents in the Chengdu–Chongqing region reached RMB12.90 per GPU-hour, up approximately 19.1% from the preceding rents. Overseas, Nebius raised its H200 on-demand rate by 20%, to US$5.40 per GPU-hour, while total contract value signed in the quarter increased almost fourfold sequentially. Rising Rents and Locked-In Long-Term Contracts Support a Roughly 3.2-Year Payback per Server On the business model, the company has signed five-year GPU leasing contracts with leading CSP and LLM customers, with approximately 12 months of rent prepaid. Assuming a purchase cost of RMB3.5m per eight-GPU server and monthly rent of RMB100,000, simple payback at full utilisation is approximately 3.2 years, and financial leverage could further shorten the payback on equity invested. Large-model developer MiniMax recently participated in the company's share placement and convertible bond subscription, which the report interprets as recognition of, and closer alignment with, the company's NCP-related procurement capabilities; cooperation could extend to resource planning and cluster deployment. On forecasts, BOCI expects FY2027–FY2029 revenue of HK$3,849m, HK$6,854m and HK$10,490m, a three-year revenue CAGR of approximately 62%, with attributable net profit of HK$216m, HK$762m and HK$1,407m. The AI Cloud server fleet expands from 531 to 4,031 units, with FY2029 AI Cloud revenue of HK$5,084.6m contributing 76.5% of group gross profit and lifting the group gross margin from 8.0% in FY2026 to 21.5%. AI Cloud will become the largest source of both revenue and gross profit. Battery Circularity and AI Infra Recycle Broaden the Earnings Base The report also notes that Hong Kong's first EV battery treatment facility, operated by the company, opened in July 2026, with the Hong Kong government projecting local retired battery volumes to rise from approximately 1,300 tonnes in 2026 to 6,700 tonnes in 2030. Battery Circularity revenue is forecast at HK$760m in FY2029. AI Infra Recycle benefits from the US copper network retirement wave — AT&T plans to shut down the vast majority of its copper services by the end of 2029 — and from its exclusive trading partnership with Fortune Metal Group, with FY2029 revenue forecast at HK$4,645.5m. 16/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Largest edition of Global Food Week opens in Abu Dhabi

EQS via SeaPRwire.com / 16/10/2026 / 09:48 UTC+8 Recently--Taking place under the patronage of His Highness Sheikh Mansour bin Zayed AlNahyan, Vice President, Deputy Prime Minister, Chairman of the Presidential Court, and Chairman of the Board of Directors of the Abu Dhabi Agriculture and Food Safety Authority (ADAFSA), Global Food Week 2026 was inaugurated by His Highness Sheikh Hamdan bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Special Affairs. Organised by ADNEC Group, a Modon company, in strategic partnership with ADAFSA, GFW is taking place until 8 October at ADNEC Centre Abu Dhabi. His Highness also witnessed the opening of the Global Food Security Summit (GFSS), attended by senior government officials, decision makers and leaders from the global agriculture and food sectors. During the visit, His Highness emphasised the importance of continuing to develop sustainable, highly efficient and future-ready food and agricultural systems by harnessing advanced technologies and artificial intelligence solutions, while strengthening public-private partnerships, contributing to enhanced food security, increasing production efficiency and improving supply chain resilience at local, regional and global levels. At the opening of GFSS, a ministerial address was given His Excellency Dr. Thani bin Ahmed Al Zeyoudi, Minister of Foreign Trade, who affirmed that ensuring the future of global food security is no longer linked solely to increasing agricultural production, but rather to building more interconnected, resilient and adaptive food systems capable of responding to rapidly evolving geopolitical shifts and climate challenges, noting that strengthening links between production centres and markets is essential to ensuring food availability and the sustainability of supply chains worldwide. His Excellency further noted that the value of the UAE’s trade in food, agricultural and related products had reached US$41.8 billion in 2025, reflecting the country’s growing role in supporting global trade flows and enhancing the security of food supplies. His Excellency added that the UAE continues to invest in future technologies and innovative solutions in the agricultural and food sectors, including vertical farming, hydroponics and precision fermentation technologies, noting that Dubai Food Tech Valley has attracted US$50 billion in investment to support efforts to develop a more sustainable and efficient food system. His Excellency emphasised the importance of aligning government and private sector efforts and accelerating investment in technology and innovation to develop practical, sustainable solutions that strengthen food security and support resilient food systems worldwide. A welcome address was given by His Excellency Dr Tareq Ahmed Al Ameri, Acting Director-General of ADAFSA, who said that Global Food Week 2026 and the GFSS represent a leading international platform for uniting efforts and strengthening cooperation among governments, international organisations, the private sector, and research and innovation institutions, while developing partnerships aimed at building more sustainable and resilient food systems capable of meeting growing demand for food amid global environmental and economic changes. His Excellency said: "We draw our vision from the legacy established by the late Sheikh Zayed bin Sultan Al Nahyan, who believed in the ability of this land to give. Today, we continue to build on that vision by harnessing modern technologies and innovation to develop a more productive, sustainable and resilient food system. We seek to raise self-sufficiency in basic food commodities to 70 per cent by 2040, improve the efficiency of natural resource use and reduce irrigation water consumption, contributing to achieving and sustaining food security for future generations." His Excellency Humaid Matar Al Dhaheri, Group CEO of ADNEC Group, said: “Global Food Week 2026 marks the largest edition in the event’s history, reflecting its growing international standing and significance as a platform that brings together all segments of the food and beverage sector under one roof. Spanning more than 42,000 square metres and bringing together 2,580 exhibitors and brands from around the world, the event creates opportunities for cooperation, trade and investment. Through this exceptional edition, we continue to strengthen Abu Dhabi as a global hub for food security, innovation and international cooperation.” GFSS, taking place under the theme Global Collaboration for Food Security for All, convenes government officials, representatives of international institutions and private sector leaders, alongside speakers from 30 countries, to discuss the challenges and opportunities shaping the future of global food security. The Republic of India is the guest of honour at this year’s Global Food Week and GFSS, reflecting the depth of the strategic partnership between the UAE and India and opening new horizons for cooperation in food, agriculture and investment. Global Food Week 2026 also witnessed the launch of the Abu Dhabi Honey Symposium & Exhibition, organised by ADAFSA in collaboration with the Apimondia, the International Federation of Beekeepers’ Associations, making it the largest specialised scientific gathering for the beekeeping and honey production sector in the Middle East and North Africa (MENA) region. The latest technologies and innovative solutions in the fields of feed manufacturing, management and efficiency development are also being showcased, enhancing productivity and supporting the UAE's efforts to develop an integrated and more efficient system for food security and sustainable animal production. The Sheikh Mansour Bin Zayed Agricultural Excellence Pavilion has attracted more than 150 award winning Emirati farmers, livestock breeders and beekeepers to showcase their products and successful experiences to investors, buyers and the public, contributing to enhancing the competitiveness of local produce and opening new marketing and investment opportunities. Company Name: Sino-International Entrepreneurs Federation Email: Carrie.zheng@sief.ae 16/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Results of on-market tender offer

EQS via SeaPRwire.com / 16/10/2026 / 04:36 MSK ASTANA INTERNATIONAL EXCHANGE LTD ("AIX"), AIX CENTRAL SECURITIES DEPOSITORY LTD (“AIX CSD”) AND THEIR RESPECTIVE RELATED COMPANIES DO NOT ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT, INCLUDING THE ACCURACY OR COMPLETENESS OF ANY INFORMATION OR STATEMENTS CONTAINED HEREIN. LIABILITY FOR THIS DOCUMENT LIES WITH THE COMPANY AND OTHER PERSONS, WHOSE OPINIONS ARE INCLUDED IN THIS DOCUMENT WITH THEIR CONSENT. NEITHER AIX NOR AIX CSD NOR THEIR RELATED COMPANIES HAS ASSESSED, APPROVED, ENDORSED OR VERIFIED THE COMMERCIAL MERITS OF THE TENDER OFFER OR THE SUITABILITY OF PARTICIPATION IN THE TENDER OFFER FOR ANY PARTICULAR SHAREHOLDER OR TYPE OF SHAREHOLDER. Solidcore Resources plc Results of on-market tender offer Solidcore Resources plc (“Solidcore” or the “Company”) announces the successful completion of its Tender Offer achieving full subscription and resulting in a total payment of US$ 1,200 million to participating shareholders. A total of 103,032,456 shares was validly tendered by Eligible Shareholders, exceeding the maximum of 102,915,952 shares available for repurchase under the terms of the Tender Offer. As a result, the shares validly tendered have been scaled back on a pro rata basis at the acceptance ratio of 0.999. Where fractions arose from scaling back, the number of shares accepted was rounded down to the nearest whole number according to the Circular. Therefore, the Company will purchase 102,915,905 shares representing approximately 23.2% of the Company’s issued share capital, at a price of US$ 11.66 per shares and for a total consideration of US$1,200 million. Payments to Eligible Shareholders in respect of the shares accepted under the Tender Offer will be made shortly after this announcement. Following settlement of the Tender Offer, the Company will hold 226,324,758 shares in treasury, and the total number of shares with voting rights in the Company will be 340,230,229. The latter number may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest (or a change therein) in Solidcore under Rule MDR 3.3 of the AIX Market Disclosure Rules. The repurchased shares will be held in treasury and will not be presently cancelled. While held in treasury, these shares carry no voting rights and no entitlement to dividends or other distributions. Percentage voting rights and per-share economic interests are calculated using the number of shares in issue excluding treasury shares. The Board considers that retaining the shares in treasury preserves flexibility over their future use where this would be in the interests of the Company, including as consideration in M&A transactions or to support liquidity in its shares, subject to applicable AIFC regulations and the Company's Articles of Association. Following settlement of the Tender Offer, Maaden International Investment SPC will hold 41.3% of the Company’s issued share capital (excluding treasury shares). “We are pleased with the strong participation in the Tender Offer which successfully delivered a substantial one-off return of capital to our shareholders. The Company maintains its solid financial position, underpinning continued disciplined investments in growth, which remains a key priority of the Company’s capital allocation policy,” – said Evgueni Konovalenko, Senior Independent Non-Executive Director, for and on behalf of the Board. About Solidcore Solidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project in Kazakhstan. Enquiries Investor Relations Media Kirill Kuznetsov Alina Assanova +7 7172 47 66 55 (Kazakhstan) ir@solidcore-resources.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@solidcore-resources.kz FORWARD-LOOKING STATEMENTS This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. 16/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Eight Consecutive Years on the Top 500 List: The Drivers Behind Huitongda Network’s (9878.HK) Resilience Across Business Cycles

EQS via SeaPRwire.com / 16/10/2026 / 09:00 UTC+8 No. Company Name Province 45 Yonghui Superstores Co., Ltd. Fujian 46 Seazen Holdings Group Co., Ltd. Shanghai Municipality 47 Vanyang Group Co., Ltd. Zhejiang 48 Huitongda Network Co., Ltd. Jiangsu 49 Yunda Holdings Group Co., Ltd. Zhejiang 50 Fujian Wanchen Group Co., Ltd. Fujian 51 Beijing United Information Technology Co., Ltd. Beijing Municipality 52 J&T Express Co., Ltd. Shanghai Municipality 53 Luckin Coffee (China) Co., Ltd. Fujian 54 ZTO Express Co., Ltd. Zhejiang 55 Suning.com Group Co., Ltd. Jiangsu 56 JiangSu Manyun Software Technology Co., Ltd. Jiangsu Recently, the All-China Federation of Industry and Commerce released the list of 2026 Top 500 Chinese Private Enterprises in Tianjin, with Huitongda Network (9878.HK, “Huitongda”) once again featured. This marks Huitongda’s eighth consecutive appearance on the ranking. It also retains its place among the Top 100 Private Service Enterprises in China, ranking 48th in this service-sector list with operating revenue of RMB 52.3 billion. A single ranking captures business scale for one year, while eight consecutive years of inclusion tells a far broader story. The retail sector has seen dramatic shifts over the past eight years. Product mixes and consumer trends have rapidly shifted toward high-frequency fast-moving consumer goods (FMCG). Retail formats have also diverged into bulk snack stores and hard-discount supermarkets, while technology tools have evolved from basic digitalisation to AI-powered systems. Each wave of change reshuffles the market, with many players rising and falling along the way. In an industry where players often enjoy only a few years of glory, what has allowed Huitongda to stay firmly in the game and consistently unlock new growth drivers? Looking back at Huitongda’s strategic choices, its starting point was not to chase market fads, but to proactively dive into the challenging yet promising lower-tier market. Its network now spans 21 provinces and 26,000 townships, serving more than 250,000 member stores. From Zhitong Finance’s perspective, scale alone is no moat. The truly scarce asset is the business ecosystem built around these township mom-and-pop shops. Products may be replaced and tools iterated, yet Huitongda’s repeatedly validated business model – centred on who it serves and the operational contexts – underpins its cycle-resilient foundation. This explains why Huitongda’s standing has steadily strengthened amid the rotating waves of e-commerce, social commerce and bulk retail. While revenue figures demonstrate Huitongda’s scale and market standing, three reusable core capabilities power the stable operation and continuous evolution of its network. First, end-to-end supply chain management capability. Huitongda’s product portfolio has shifted from its early product lines defined by three key traits – high after-sales service demands, high customer experience requirements and high unit prices – to today’s high-frequency FMCG such as snacks and convenience goods. Yet its full-chain capability to move goods from factories to retail outlets remains robust. New product categories tapping into its established network immediately benefit from Huitongda’s mature channel operating efficiency. This is the primary driver behind its faster category expansion versus peers. Second, customer service capability. Merchants in lower-tier markets have limited digital foundations; rolling out a system does not mean merchants can use it effectively. Huitongda’s county-level field teams handle promotion, training and ongoing operations, ensuring every upgrade translates into tangible in-store business activities. This delivers lower customer acquisition costs and stronger retention compared with purely online models. Third, technological capability. Its tech stack has evolved across three phases: lower-tier market e-commerce, industrial internet, and now AI. The user base and real-world use cases built through the first two phases provide groundwork for technological iteration. Technology can be purchased from external vendors, but the user scenarios and underlying data foundation required to deploy it are not purchasable. These three layers of capabilities reinforce one another. The core foundation stays robust while capabilities grow over time – this is the essence of cross-cycle resilience. As the retail sector enters a new era shaped by smart supply chains and AI, the value of these three capabilities becomes even more apparent. AI deployment in lower-tier markets faces three distinct hurdles not seen in urban markets. The first hurdle lies in real-world scenarios. General foundational models are mostly trained on data from highly standardised urban supermarkets, with little representation of the unstandardised retail landscape in lower-tier markets. Actual business activities themselves are a scarce resource. Huitongda’s multi-format store network and daily workflows including sales, ordering, inventory management, product selection and promotions enable continuous model calibration against live business data. Companies without on-the-ground scenarios can only provide tools; those embedded within real business operations can deliver tangible outcomes. The second hurdle is a closed data loop. Huitongda serves three customer groups within its ecosystem: member stores, chain outlets and e-commerce merchants. Product selection and operational insights from member stores are reused for chain stores. High-frequency transactions at chain outlets feed back into the model. E-commerce use cases supplement online datasets. Scenarios generate data, data refines models, and refined models feed back into scenarios, forming a closed loop that lifts efficiency over time. Even if competitors build models of comparable performance, they lack the live scenarios and data needed for ongoing calibration and iteration. The third hurdle is delivery. The limited digital maturity of lower-tier merchants means AI tools cannot be rolled out purely online. Deployment and sustained usage rely on offline support. Huitongda’s county-level field teams manage outreach, training and ongoing operations, making its AI offering service-led rather than traffic-driven, and delivering more predictable user renewal and retention. This represents a natural extension of its customer service capability into the new cycle. While eight years of ranking recognition reflects operational scale, the foundation forged from users, real-world scenarios and capabilities defines sustainability – the scarcest source of cross-cycle investment value. By integrating more than 250,000 township mom-and-pop stores into its digital ecosystem, Huitongda fosters a virtuous loop where commercial viability and social impact reinforce one another. A more robust foundation translates into greater certainty of returns. As smart supply chains and AI use cases, exemplified by snack and convenience retail formats, gain growing traction across lower-tier markets, the capabilities built atop this foundation stand to deliver operating results and shareholder returns at an accelerated pace. 16/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Sustained Positive Same-Store Transaction Count Growth: DPC Dash (1405.HK) Strengthens Its Pizza Foundation

EQS via SeaPRwire.com / 15/10/2026 / 17:43 UTC+8 After the peak wave of food delivery subsidies faded, platforms have prioritized per-order efficiency while consumers focus more on out-of-pocket prices. With a high share of delivery orders and strong demand for group sharing, pizza businesses are more sensitive to changes in average transaction price (ATP) and fulfillment costs than other fast-food businesses. Against this backdrop, chain pizza brands face a starker efficiency test than most catering players. DPC Dash Ltd’s Q3 2026 operating data reveals an important thread when viewed within this context. Same-store transaction count posted healthy year-on-year growth, average transaction price stabilized, and the store and member base expanded. As competition in the pizza sector shifts to an efficiency-driven phase, Q3 data offers insights into whether DPC Dash can build a virtuous cycle across scale, brand, delivery network and membership programme. 01 Positive Transaction Count Growth, Stabilizing Pricing As platform subsidies become more rational, orders generated purely through low pricing decline, and brands must capture genuine consumer demand. This is especially true for pizza: consumers are price-sensitive and also demand reliable delivery times. When delivery subsidies taper off, higher effective prices may cause some consumers to hold back, putting short-term pressure on transaction volumes. DPC Dash continued to deliver solid same-store transaction count growth in Q3, demonstrating resilient underlying demand. Price sensitivity triggered by fading subsidies has not eroded consumer appetite, supported by its product portfolio, delivery brand mindshare and member base. Meanwhile, the Company rolled out targeted marketing initiatives, enabling average transaction price to stabilize and edge up quarter-on-quarter. Same-store sales growth remained negative, dragged mainly by average transaction price, which was still lower than the level recorded in Q3 2025. The core metric for catering same-store performance is volume multiplied by price. With volumes growing healthily and prices on the mend, same-store sales growth stands to improve once year-on-year declines narrow. It is critical to distinguish same-store transaction count growth from same-store sales growth. Same-store transaction count reflects demand momentum, while same-store sales represent top-line revenue reported in financial statements. Demand recovers first, followed by pricing repair — a common trajectory for catering chains after subsidy pullbacks. Notably, stabilizing ATP signals that the period of greatest pricing pressure is easing. DPC Dash’s Q3 results sit in the early stage of this cycle: the combination of rising volumes and steady pricing has emerged, and a recovery in same-store sales is only a matter of time. Delivery operations in new city markets are also advancing. Delivery transaction volume accounted for 30% of total volume in these markets in Q3, up from 25% in the first half. Third-party aggregator platforms remain a vital channel for rolling out delivery services in new cities, helping stores quickly build fulfillment capabilities and reach users. This is intuitive: delivery infrastructure in newer markets is less mature than in first-tier cities, and third-party platforms’ traffic portals shorten the ramp-up period. Over the long run, members and proprietary channels determine profit margins. Third-party platforms carry commission and subsidy costs, whereas proprietary channels deliver higher profit margins. DPC Dash adopts a pragmatic approach for new markets: it leverages third-party platforms to gain initial traction before gradually converting customers into members. 02 Anchored Store Network, Expanding Member Reservoir Once catering chains reach the thousand-store milestone, expansion bottlenecks tend to stem not from capital or site selection, but organization, supply chain and repeat purchases from members. A larger store network complicates standardization, and unit economics may deteriorate as the network expands. As at 30 September 2026, DPC Dash operated 1,634 stores across 87 cities. The Company added a net of 319 stores and entered 27 new cities from January to September. Its full-year target of roughly 350 net new stores is fully secured, covering newly opened, under-construction and signed outlets. A major risk for catering chain expansion is disrupted rollout cadence; the locked-in target shows a closed-loop execution pipeline spanning site selection, contracting, store construction and launch, with high delivery certainty. Greater store density boosts delivery fulfillment efficiency, brand exposure and member outreach. Member data forms another layer of foundational strength. The member base reached 45.2 million, up 37.4% from 32.9 million a year earlier. Over the past 12 months, 19.9 million new customers placed their first order. A larger member pool means new product launches and marketing campaigns no longer rely solely on platform subsidies; repeat purchases translate into more stable demand. Pizza consumption frequency is relatively moderate, yet group-sharing and delivery scenarios support steady repeat visits. A bigger member base enables refined user segmentation, lifting consumption frequency and average transaction price. Mutual reinforcement between the store network and brand momentum constitutes one of DPC Dash’s harder-to-replicate strengths in the pizza sector. Combined with efficiency gains from its self-built central kitchens and standardized store operations, the Company is building a virtuous cycle between scale expansion and management efficiencies. 03 Marketing Buzz; Repeat-Purchase Traction Catering marketing has grown increasingly frequent, with holiday-limited editions, co-branding campaigns and promotions commonplace, while consumer attention becomes scarcer. Running promotions is not difficult for brands; the challenge lies in retaining consumption habits once campaigns end. DPC Dash rolled out multiple product initiatives in Q3. It launched the Salted Egg Yolk Flavored Star & Moon Pizza for the Mid-Autumn Festival, weaving festive motifs around its core Salted Egg Yolk Flavored Chicken Pizza. For the Major Heat solar term, it ran a playful pun campaign, “Da Shu Shi Shu” (a Chinese homophone pun meaning “eat potato in Major Heat”), to promote its signature potato pizza range. The new Durian Roast Chicken Pizza combines chunks of durian pulp with roasted chicken to deliver differentiated flavour. It also introduced a RMB79 six-piece bundle including two 9-inch pizzas plus side dishes and beverages, alongside solo meal sets catering to single-diner occasions. In September, it held a “Buy One Get One Free” Mega Week promotion. Marketing messaging has also leaned younger. During the Buy One Get One Free campaign, slogans such as “Favorite Brands and Flavors – You Have it All”, “Second One On The House”, and “Pizza Freedom” were deployed. Its REDNote campaign “Finding Domino’s Red and Blue” boosted consumer engagement, broadened pizza consumption scenarios and entrenched brand mindshare. These moves deserve deeper analysis beyond surface-level buzz. The quarter-on-quarter uptick in average transaction price shows the Company has struck a balance between traffic generation and pricing. High value-for-money bundles and Buy One Get One Free promotions lift transaction volumes, while new products and holiday marketing boost average transaction price and brand heat. Coupled with the expanding member base, these efforts convert new users into active members and raise member engagement and repeat purchase frequency. 04 Conclusion Overall, DPC Dash’s Q3 operating data paints a fuller picture than standalone financial figures. Robust same-store transaction count growth proves resilient underlying demand; the quarter-on-quarter recovery in average transaction price signals recovering pricing power; locked store expansion targets reflect controllable rollout cadence; and rapid member growth shows a deepening reservoir of repeat customers. After subsidies normalize, competition in the pizza sector returns to products, operational efficiency and user assets. DPC Dash’s scale, brand, delivery network and membership programme are forming a powerful combination. Near-term results show promise, while long-term foundations are being reinforced. The pizza business is undergoing this strategic shift and merits continued monitoring. 15/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Global Food Security Summit Concludes in Abu Dhabi with Renewed Commitment to Strengthening Global Food Security

EQS via SeaPRwire.com / 09/10/2026 / 14:36 UTC+8 Abu Dhabi-UAE – The second edition of the Global Food Security Summit (GFSS) concluded at ADNEC Centre Abu Dhabi after two days of discussions held under the patronage of His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister, Chairman of the Presidential Court, and Chairman of the Board of Directors of the Abu Dhabi Agriculture and Food Safety Authority (ADAFSA). The summit took place on 6 and 7 October 2026 as part of Global Food Week. Organised by ADNEC Group, a Modon company, and hosted by ADAFSA, with the support of the Ministry of Climate Change and Environment (MOCCAE), the summit reaffirmed Abu Dhabi’s role as a global hub for dialogue, partnership and innovation in food security. By convening governments, international organisations, financial institutions, investors, industry leaders and experts, the event contributed to advancing collaborative action towards more resilient, sustainable and inclusive food systems worldwide. Held under the theme “Global Collaboration for Food Security for All,” GFSS 2026 drew broad participation from governments, international organisations, financial institutions, investors, academia, industry leaders and innovation experts. Discussions focused on strengthening partnerships, mobilising investment and accelerating collective action to address global food security challenges, with participants emphasising the importance of transforming commitments into practical actions and measurable outcomes that support the development of more resilient, sustainable and inclusive food systems worldwide. The participation of the Republic of India as Guest of Honour was among the key highlights of this year’s summit, underscoring the depth of the strategic relationship between the UAE and India. The participation provided a valuable opportunity for the exchange of knowledge and experiences in food security, agricultural innovation and sustainable development, further strengthening cooperation between the two countries in these vital sectors. His Excellency Dr. Tariq Ahmed Al Ameri, Acting Director General of ADAFSA, said: “The second edition of the Global Food Security Summit reflected Abu Dhabi’s vision of transforming global dialogue into practical partnerships and initiatives that support the development of more resilient food systems capable of adapting to future challenges. The summit successfully brought together policymakers, investors, innovators and experts from around the world on a single platform to discuss shared solutions and strengthen international cooperation in this vital field.” He added: “The discussions and outcomes of the summit underscored the importance of leveraging innovation, technology and advanced data to strengthen global food security. They also highlighted the pivotal role of international partnerships and targeted investments in supporting sustainable food production and enhancing supply chain efficiency. Through such initiatives, the UAE continues to reinforce its position as an active international partner in shaping a more secure and sustainable food future.” His Excellency Humaid Al Dhaheri, Group CEO of ADNEC Group, said: “The Global Food Security Summit served as a leading international platform for dialogue and knowledge exchange among experts, decision-makers and partners from around the world. The strong participation and momentum witnessed throughout the summit reflect the importance of this global event and its role in supporting efforts to enhance food system resilience and unlock high-impact investment in this crucial sector.” He added: “ADNEC Group remains committed to supporting platforms such as the Global Food Security Summit, which further strengthen Abu Dhabi’s position as a global hub for dialogue on food security and sustainable development.” Over two days, the summit addressed a broad range of issues related to global food security, including international cooperation and food diplomacy, climate-resilient agriculture, strategic food corridors and trade, AI-driven food systems, food and nutrition security, as well as the role of innovation and technology in enhancing the resilience of food systems and global supply chains. The summit concluded with a renewed commitment to strengthening international cooperation, investing in agricultural and food innovation, accelerating knowledge exchange among stakeholders, and advancing collaborative solutions that support global efforts to achieve the Sustainable Development Goals, eradicate hunger and build more resilient, sustainable and future-ready food systems. 09/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Clinical Screens in Melbourne, Data in Chicago, Foundational Models in Hangzhou: Tracing Medical AI’s Trillion-Dollar Value

EQS via SeaPRwire.com / 09/10/2026 / 14:11 UTC+8 Today, after a patient completes a chest CT scan, clinicians pull up the images, review prior test results and treatment histories, and interpret what the new findings signify. Tomorrow, the next wave of trillion-dollar medical AI companies will likely emerge from three pillars: clinician workflow systems used day-to-day, datasets spanning the entire patient care journey, and foundational models that continuously deliver new diagnostic capabilities. Tracing this trajectory reveals three global hubs. Pro Medicus (ASX: PME) in Melbourne, Australia, built its business around imaging workflows; Tempus AI (NASDAQ: TEM) in Chicago, US, focuses on diagnostics and patient data; Diagens Tech (HKEX: 2526) in Hangzhou, China, innovates with medical imaging foundational models. As of 8 October 2026, their respective market capitalisations stood at approximately RMB 78 billion, RMB 84 billion, and RMB 22 billion. Each company began with a distinct business focus: Pro Medicus primarily sells imaging software; Tempus generates most of its revenue from molecular diagnostics and data services; Diagens Tech deploys medical imaging large foundational models into hospitals and clinical practice. Together, they illuminate a critical industry question: if workflows and data already command high valuations, could models that continuously generate clinical capabilities become the third high-value asset class in medical AI? This article argues that Diagens Tech is positioning itself to occupy exactly this niche. By expanding from one regulated use case to additional specialties and hospital sites, it empowers clinical specialists to build, deploy and operate thousands of custom models on one unified foundation. As AI infinitely amplifies specialist expertise, medical imaging foundational models evolve from standalone technology products into scalable platform assets. A Paradigm Shift: Health Demands Answers, and Above All, Evidence The arrival of large models in healthcare reshapes how people engage with health information. In 2026, OpenAI rolled out health features that connect to medical records and Apple Health with user consent, reporting that more than 300 million people submit health queries to ChatGPT each week. Health management may shift from sporadic web searches to continuous insight, reminders and follow-up queries. Even so, while large language models can interpret reports, they cannot validate tumour shrinkage or organ damage from that data alone, let alone deliver reliable forecasts of disease progression. On another frontier, AI is transforming drug discovery. Google DeepMind’s AlphaGenome examines how genetic variants alter molecular properties; NVIDIA and Eli Lilly announced up to USD 1 billion joint investment over five years; Rentosertib, a candidate drug co-developed by Insilico Medicine, entered Phase Ⅲ trials in 2026. From molecular hypotheses to clinical trials, models now contribute to discovery and R&D decisions. Health management seeks to understand what occurs within the body, while drug development explores how treatments alter disease outcomes. Both rely on reproducible, observable clinical evidence. As the primary source of clinical evidence, medical imaging covers roughly 14,000 indication-specific tasks across CT, MR, ultrasound, endoscopy, pathology, microscopy, dermatoscopy and fundus imaging, accounting for 80% of all global clinical data. According to the World Health Organization, over 25 billion medical imaging scans are performed worldwide each year. This massive volume makes imaging one of the richest, most reliable observation layers within healthcare systems. Medical records, comparatively, are human-language documentation of those core observations. Model development and clinical trials are converging in medical imaging. Google’s MedGemma 1.5 delivers interpretation for 3D CT, MRI and pathology images, while Microsoft’s CARE‑X focuses on chest X-ray reading and lesion localisation. The Swedish MASAI randomised trial enrolled approximately 106,000 women. Within a defined breast screening pathway, the AI-assisted workflow achieved higher breast cancer detection sensitivity (80.5% versus 73.8%), with comparable false positive control (98.5% specificity in both arms). Advances in technical performance and clinical evidence are converging. The next question defining industry value centres on integrating these capabilities into clinicians’ daily tools and building sustainable revenue streams. Pro Medicus’ Screens in Melbourne: Imaging Information Management Software — Embedded in Clinicians’ Daily Workflows The “screens” referenced here refer to end‑to‑end workflow management software for clinicians to view, compare and analyse medical images. Pro Medicus’s Visage7 integrates image viewing, archiving and workflow management. Clinicians open, review and compare imaging data on this system every day. Going forward, once hospitals organise image reading, reporting and cross‑institutional collaboration around this platform, the software may become central to clinical operations. This pathway has delivered tangible commercial outcomes. In fiscal2026, Pro Medicus recorded approximately AUD261.7million in revenue and AUD127.5million in operating cash inflow, with disclosed minimum contracted revenue of around AUD1.3billion over the next five years. The market assigns it a valuation well above its current‑period revenue. Long‑term contracts, workflow‑embedded products and proven cash‑generating capacity underpin this valuation. Melbourne demonstrates the first key insight: in high-frequency, trust-reliant healthcare settings, the daily access portal used by clinicians is itself a valuable asset. Yet smooth image visualisation only addresses operational needs. To interpret what imaging findings mean for an individual patient, clinicians also require the patient’s diagnostic, examination and treatment context. Tempus’ Data in Chicago: Connecting Single Tests to a Patient’s Lifelong Care Journey Tempus offers a second benchmark. Its core revenue comes from molecular diagnostics – understanding disease via genetic and molecular information – linking test results, clinical records, data applications and pharmaceutical R&D needs. Its implications for the industry are that value can extend beyond diagnosis when textual data connects a patient’s long‑term disease trajectory, treatment decisions and real‑world outcomes. In Q2 2026, Tempus generated USD382.5million in revenue, including USD289.3million from diagnostics and USD93.2million from data and applications. Tempus also disclosed delivery of the first version of its oncology foundational model to AstraZeneca. Tempus’s valuation reflects data generated by its diagnostic business, capabilities for deploying data to clinicians and pharmaceutical companies, and its sustained revenue growth. Diagens Tech’s Foundational Model in Hangzhou: Turning Clinicians from Users into Creators The promising future of medical AI emerges from a recent in-depth conversation between Dr. Ning Song, Founder and Chairman of the Board of Diagens Tech and Kevin Kelly, founding editor-in-chief of WIRED, the renowned global technology publication. Dr. Song drew an analogy between print shops and office productivity software. Document creation once required outsourced typesetting and printing, a slow and costly process. After document-editing tools became accessible on personal computers alongside printers, the volume of documents people could create exploded. Yet global healthcare still operates differently: vendors select disease areas, build AI tools independently and hand finished products to hospitals. Spending RMB 300 million over three years to build one disease-specific imaging AI tool remains common. Dr. Song envisioned a comparable shift: radiologists can leverage state-of-the-art imaging foundational models to train custom diagnostic AI rapidly, accurately and affordably for their own specialties. He described this future medtech ecosystem as “a flourishing bloom of custom clinical AI solutions”. While endorsing this innovative framework, Kevin Kelly noted that for a world-leading medical AI company, the journey to realise this vision forms its strongest competitive moat. Medical imaging foundational models operate on a simple principle: learn general anatomy and lesion characteristics from vast libraries of CT, ultrasound and pathology scans, then adapt to targeted clinical assessments using specialty-specific patient cases. The shared foundation absorbs the heavy upfront investment, allowing new use cases to reuse existing capabilities. Diagens Tech discloses its iMedImage® foundational medical imaging model spans 19 imaging modalities and 26 clinical specialties. For certain low-data scenarios, a specialty model can be trained within two to three months using roughly 200 imaging samples. Its iMedMaaS® model training and deployment platform enables clinicians to run no-code training and on-premise deployment using in-hospital datasets. Hospitals thereby shift from purchasing off-the-shelf algorithms to defining clinical challenges and co-building tools. For this production system to work, image volume is only the starting point; clinical expertise must be integrated into datasets. Diagens Tech reports that iMedImage® was trained on more than 80 million medical images. Its iMedLoop™ medical imaging AI R&D and production acceleration platform hosts 28.95 million annotated records, built with contributions from over 3,000 specialised professionals. A “record” refers to one sample entry, which may contain multiple images – much as a single CT scan generates sequential slices. Raw scans expose the model to diverse anatomical variations, while expert annotations identify lesion locations and classification rules. Annotation, quality control and evaluation transform raw image data into usable clinical knowledge for model training. Hospitals can also train models locally using their own data. As of mid-2026, Diagens Tech had partnered with 99 hospitals to deliver 158 model projects. New clinical challenges defined by hospitals, paired with annotation and evaluation frameworks co-developed by specialists, form building blocks for future applications. Notably, the number of models Diagens Tech trains within a single year exceeds the total volume of medical imaging AI models developed across China in the past decade. Translating this production capacity into clinical adoption requires market-ready products and paying customers. AI AutoVision®, built on iMedImage®, is software designed to help clinicians analyse karyograms and detect abnormalities. It obtained Class III medical device registration from China’s NMPA in May 2026. In its clinical trial, the “clinician+AI” workflow delivered readings in an average of 11.3 minutes, compared with 34.1 minutes for conventional workflows. In the first half of that year, Diagens Tech generated RMB 94.541 million in model service revenue via model and technology licensing, cloud services and on-premise deployment, marking year-on-year growth of 101.1%. The registered product demonstrates how foundational models translate into clinical use, while model service revenue confirms customers are paying for model generation and delivery capacity. The vision of “flourishing bloom” therefore gains commercial substance: clinicians define new clinical challenges, and the platform continuously delivers specialty capabilities using a unified toolset. The Trillion-Dollar Question: From an Imaging-AI Factory to Disease-Interpretation Infrastructure What challenges does this “factory” need to tackle? Medical imaging diagnostics cover 14,000 indication-specific tasks. This count refers neither to hardware nor individual images, but to distinct examinations designed for separate clinical objectives. Even for chest CT, lung cancer screening, pulmonary embolism detection and pneumonia assessment represent separate indications, requiring different imaging protocols and clinician interpretation workflows. Each task demands specialised capabilities; medical imaging forms a vast, fragmented landscape of clinical requirements. Scale brings its own constraint: many clinical conditions lack sufficient patient samples. A study published in Nature Communications identified 5,568 imaging-linked diseases and anomalies across more than 40,000 patient cases, many represented by fewer than 30 samples. The traditional “one model for one disease” paradigm requires fresh case collection, expert annotation, training and validation for every new task. Costs and timelines compound when addressing tens of thousands of niche use cases. Cross-task reusable foundational models embed shared imaging comprehension within a single foundation, allowing clinicians to adapt models using specialty-specific samples. This makes it feasible to cover these long-tail clinical needs at a manageable cost. The true expansion enabled by foundational models lies in the total volume of clinical capabilities that can be built. This factory unlocks another capability: supporting researchers to frame new questions about disease progression. Imaging captures physical changes within the body. When linked to pathology, genetics, treatment records and patient outcomes, models can probe: which early markers signal recurrence? Which patients will respond best to a given therapy? This is AI for Science in medical imaging: identifying correlations from large-scale clinical observations and generating testable medical hypotheses. Research published in Nature Cancer has sought to infer tumour gene expression from pathology slides to predict therapeutic response. Diagens Tech’s research advances along this same path. Its iMedImage® technical report reveals the team combined contrast-enhanced CT, clinical and pathological data to predict one-year post-surgical recurrence risk for pancreatic cancer, achieving an AUC of 0.78 across 89 external test samples. An AUC value closer to 1 denotes stronger ability to stratify patients by risk. A separate study combines cervical ultrasound and maternal clinical histories to forecast preterm birth risk. Model research is shifting its focus from “what can be observed today” to “how disease may evolve over time”. In September 2026, Diagens Tech established a joint laboratory with the Hong Kong Polytechnic University to investigate medical imaging analysis, healthcare foundational models and research workflow automation. The logical thread spanning these three cities now forms a complete loop. Pro Medicus owns the daily software access portal for clinicians; Tempus integrates textual findings into AI-powered long-term patient journey databases for diagnostics and pharmaceutical R&D; Diagens Tech builds a production platform empowering clinicians worldwide to build new models. Its growth follows two clear vectors: expanding into more hospitals, and addressing numerous specialty AI diagnostic needs within each site. Shared foundational models cut development costs for new tasks. Extending beyond diagnosis into prognosis, patient stratification and treatment response research opens opportunities to serve academic institutions and life science companies. This reveals a new dawn for human health management, as the field shifts from Cure Medicine toward Care Medicine. Amid the promising outlook for human well-being, the three cities, three pathways and three sets of valuations remain underappreciated. Diagens Tech’s growth journey represents humanity’s quest to manage health more effectively and precisely. Melbourne shapes clinicians’ daily workflows, Chicago maps patients’ lifelong care journeys, and Hangzhou establishes a new benchmark for human health. At the frontiers of AI, we welcome a new era of human well‑being. 09/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Global Food Week 2026 to open in Abu Dhabi on October 6 with a record 2,580 exhibitors

EQS via SeaPRwire.com / 06/10/2026 / 12:15 UTC+8 Second Global Food Security Summit to run alongside the event, with participants from 30 countries ABU DHABI, Oct. 5, 2026 — Global Food Week 2026 will be held from October 6 to 8 at ADNEC Centre Abu Dhabi, the largest edition of the event to date, organiser ADNEC Group said at a press conference. The event is organised in strategic partnership with the Abu Dhabi Agriculture and Food Safety Authority (ADAFSA). Exhibition space will cover approximately 42,000 square metres, a 25 percent increase compared to the previous edition, while exhibitors and brands total 2,580, an 18 percent year on year increase. Participating countries and regions have increased to 92, a 23 percent increase compared to 2025, including 26 first-time participants. National exhibitors account for 67 percent of the total, international exhibitors 33 percent, and small and medium-sized enterprises 22 percent of exhibiting companies. The second Global Food Security Summit (GFSS) will be held alongside the exhibition and will bring together representatives of governments, multilateral institutions and the private sector. Participants from 30 countries will discuss how food systems can move from resilience towards readiness for future disruptions, covering emerging challenges, innovative technologies, investment opportunities and policy frameworks. Those attending the press conference included Ahmad Shaker, CEO of Capital 360 & Events, Badr Hassan Al Shihi, Director of the Communications and Community Engagement Department at ADAFSA. His Excellency Prof. Abdelouahhab Alboukhari Zaid, Secretary General of the Khalifa International Award for Date Palm and Agricultural Innovation, affiliated with Erth Zayed Philanthropies Foundation, UAE Presidential Court; Ahmad Mukhtar, Subregional Coordinator for the Gulf Cooperation Council States and Yemen and FAO Representative to the United Arab Emirates and Saleh Lootah, Chairman of the UAE Food and Beverage Manufacturers Group. "This edition is witnessing record growth across all key indicators," said Ahmad Shaker, CEO of Capital 360 & Events, who added that Global Food Week continues to strengthen its position as an international platform for food security, agricultural innovation and sustainable development. Badr Hassan Al Shihi, Director of the Communications and Community Engagement Department at ADAFSA, said the event introduces a business-to-consumer (B2C) model for the first time, combining business, investment and trade with a direct consumer experience. The 2026 edition spans eight sectors along the food value chain. A dedicated Animal Feed Sector is introduced for the first time, an enhanced Shop to Show feature allows visitors to buy directly from local and international exhibitors, and the ACCESS Abu Dhabi programme will connect more than 150 award-winning Emirati farmers, livestock breeders and beekeepers with buyers, investors and the public. In addition, the event will host the inaugural Abu Dhabi Honey Symposium in collaboration with Apimondia, the AgriTech Forum, and a Hosted Buyers Programme linking international companies with local suppliers. His Excellency Prof. Abdelouahhab Alboukhari Zaid said the Abu Dhabi Date Palm Exhibition has become a cornerstone of Global Food Week and that its role reinforces Abu Dhabi's position as a hub for dialogue, innovation and strategic partnerships. Ahmad Mukhtar said FAO will continue to work with the UAE Ministry of Climate Change and Environment, ADAFSA, ADNEC Group and other partners to advance safe, nutritious and sustainable food. Saleh Lootah said food security is a collective responsibility that requires closer international cooperation. The 2025 edition generated 58 cooperation agreements worth a total of AED 6.6 billion, and FAO and the Sub-Regional Office for the Gulf Cooperation Council States and Yemen of the World Organisation for Animal Health will take part again this year. Global Food Week runs from October 6 to 8 at ADNEC Centre Abu Dhabi and is open to the public and to industry professionals, who can see the latest innovations, meet industry leaders and take part in a range of food-focused events and activities. 06/10/2026 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

FISG and Andrés Iniesta Mark Strategic Partnership with Official Signing Ceremony in Dubai

EQS via SeaPRwire.com / 06/10/2026 / 11:44 UTC+8 Dubai, UAE - October 06, 2026 - (SeaPRwire) - FISG – InterStellar Group officially marks its strategic collaboration with global football icon Andrés Iniesta with a signing ceremony in Dubai on September 25, 2026. The ceremony represents a key milestone in FISG's international brand development and its commitment to building long-term partnerships that connect financial expertise, global reach and excellence. As part of the collaboration, Andrés Iniesta serves as Global Brand Experience Officer, contributing his international experience, professional values and global perspective to FISG's brand vision. Where Speed, Agility and Experience Meet This partnership brings together two worlds defined by the ability to master the moment where speed, agility and experience turn opportunity into lasting success. Iniesta's career is built on reading the game in split seconds, adapting with agility, and delivering when it matters most. FISG – InterStellar Group shares that same mindset: moving with speed in fast-changing markets, acting with agility across global operations, and drawing on decades of experience to deliver for clients worldwide, all underpinned by four-tier regulatory (CySEC,FSCA,ASIC,FSP) oversight, ensuring the highest standards of governance, transparency and client protection across every market it serves. Together, the partnership reflects a shared commitment to discipline, consistency and the pursuit of excellence. A Partnership Built on Shared Values The official signing ceremony takes place in Dubai, bringing together representatives of FISG, Andrés Iniesta, and invited partners and guests. "This partnership represents more than a collaboration between a global broker and one of the most respected names in international sport. It reflects shared values of discipline, trust, consistency and long-term excellence," said Konstantinos A. Theodorou, CEO of InterStellar Group. Andrés Iniesta added: "I am pleased to be part of this new chapter with FISG. The values behind the partnership - professionalism, discipline, teamwork and a commitment to excellence are values I strongly believe in. I look forward to contributing to the journey ahead." Looking Ahead The signing ceremony marks the beginning of a broader international collaboration between FISG and Andrés Iniesta, with further initiatives and brand experiences to be announced in the future. FISG – InterStellar Group continues to strengthen its international presence and develop a global brand built around its philosophy:Decades of Trust · Velocity Worldwide. About FISG FISG is a global platform bringing together forex, trading, investment, and fintech professionals. It connects brokers, investors, financial service providers, technology companies, and industry experts. The summit focuses on networking, business partnerships, market insights, and industry discussions. It provides participants with opportunities to showcase their solutions and connect with potential clients and partners. FISG also creates a space for meaningful conversations around the future of global financial markets. Media Contact Brand: FISG Contact: Media team Email: mkt@fisg.com Website: https://fisg.com/en/home 06/10/2026 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Silicon Valley “Godfather” Kevin Kelly: AI’s Core Asset Is the Ability to Keep Building New AI Systems

EQS via SeaPRwire.com / 02/10/2026 / 10:49 UTC+8 Google’s MedGemma 1.5 can interpret multimodal medical images, including CT and MRI scans and pathology slides. OpenAI’s health features can answer questions by combining medical records with sleep and activity data. Yet as the technical capabilities of medical AI advance, a fundamental tension remains: medical AI has no fixed set of “standardized” answers. Clinicians can read the same scan differently. New disease entities and diagnostic modalities continue to emerge, meaning that even today’s most advanced models may need to be rebuilt within a few years. What lies ahead for medical AI? On Sept. 25, during the fifth Global Digital Trade Expo, Dr. Ning Song, founder and chairman of the board of Diagens Tech, had an in-depth conversation with Kevin Kelly, the founding editor-in-chief of Wired magazine. Their conversation brought a shift into focus: as the line between AI and clinicians is redrawn, the competitive dynamics of medical AI are quietly changing. What Is the Real Competitive Moat in Medical AI? As AI takes on more medical information processing and diagnostic tasks, the division of work between AI and clinicians is being redefined. Kelly believes AI outperforms humans in providing medical information and performing diagnostic tasks, while clinicians bring empathy and the capacity for breakthrough innovation—capabilities AI cannot replicate. Amid rapid technological progress, clinicians need to keep learning throughout their careers, while AI systems must continue to evolve. Customizable medical imaging AI developed for individual hospitals and clinicians allows clinicians to play a greater role in developing the technology, feeding their professional expertise into ongoing model training. That view aligns closely with Diagens Tech’s approach in practice. The company believes medical AI will thrive through collaboration between humans and AI. In the future, radiologists will be able to solve their own specialized clinical challenges and train tailored AI copilots based on a shared foundation model. This “clinician-as-developer” model points to a shift in the medical AI business model, from selling software to providing capabilities. Software will become obsolete, but capabilities can be reused and monetized on an ongoing basis. This may be a key way for medical AI companies to build a lasting competitive moat. A Full-Stack Product Suite: From Data Accumulation to Clinical Deployment At the fifth Global Digital Trade Expo, Diagens Tech showed how medical imaging data can drive AI-enabled productivity. Its product suite has four layers: iMedImage® is the foundation model for medical imaging; iMedStudio™ lets specialists participate in data annotation, correction and quality control; iMedMaaS® supports the training and deployment of models for specific specialties; and iMedLoop™ links data collaboration, evaluation, release and feedback. Specifically, iMedStudio™ handles medical image processing, AI-assisted annotation, expert review and quality control. The platform now has more than 3,000 professional annotators and a high-quality medical imaging dataset of 28.95 million records. iMedLoop™ comprises four core modules: iMedStudio™, a workspace for multimodal intelligent annotation and data production; iMedImage®, a large-scale foundation model for medical imaging; iMedMaaS®, a model-training and deployment platform; and DoctorBench®, a unified evaluation system. Together, these modules facilitate secure data collaboration across institutions. Building on this infrastructure, Diagens Tech showcased more than 20 representative use cases in obstetrics and gynecology, growth and development, cardiovascular and cerebrovascular conditions, emergency and critical care, and oncology. They span imaging modalities including CT, MRI, X-ray, ultrasound, CTA and endoscopy. All draw on the underlying capabilities of iMedImage®, the universal foundation model for medical imaging. Diagens Tech describes its end-to-end pipeline—from accumulating medical imaging data and generating high-quality data to developing and training models and deploying them clinically—as an accelerator for medical imaging AI research and production. Rather than rely on any single model’s superiority, it uses closed-loop workflows to build a production system that can be updated continuously, directly addressing medical AI’s fundamental challenge: clinical scenarios are neither standardized nor static. To date, Diagens Tech has made substantial progress in regulatory compliance and commercialization. AI AutoVision®, its karyotype-assisted diagnostic software built on iMedImage®, received Class III medical device registration from China’s National Medical Products Administration (NMPA) this year. The iMedImage program covers 43 human organs or anatomical sites and 61 disease areas. Diagens Tech has established partnerships with 99 hospitals, including 65 Grade A tertiary hospitals. Looking ahead, Kelly says a company’s real long-term core asset may be neither its software nor its algorithms, but a repeatable process for creating new software, new algorithms and, above all, new medical imaging AI systems. This marks a fundamental shift in how medical AI companies compete. In the past, the industry competed to build the most advanced models. In the future, competition will center on the ability to build models tailored to new use cases continuously, efficiently and in a compliant manner. Diagens Tech’s universal foundation models and suite of tools fit this transition perfectly. With reusable foundation layers, accumulated data and closed-loop workflows, every deployed project fuels further expansion, creating a self-reinforcing platform flywheel that grows stronger with use and drives exponential business growth. If this roadmap succeeds, Diagens Tech is poised to become a platform leader by 2030, with annual revenue in the RMB 10 billion range, net profit of RMB 3 billion and market capitalization exceeding RMB 200 billion. Its ability to keep evolving represents the sector’s scarcest valuation anchor today. 02/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

World Premiere: MirrorMe’s Dexterous Hand VIVA Enables Real-Time Human-Robot Four-Hand Piano Duet; VIVA × CADA Milestone Unveiled

EQS via SeaPRwire.com / 29/09/2026 / 10:26 UTC+8 MirrorMe today unveiled its dexterous robotic hand VIVA, achieving the world’s first real-time human-robot four-hand piano duet. Moving beyond rote note-for-note playback, the robot can now play with genuine musical expression. MirrorMe also announced the completion of the VIVA × CADA milestone, marking a new frontier in robotic musical intelligence. Powered by this pairing, robots gain capabilities to compose, perform and iteratively learn—evolving from pre-programmed motion executors into interactive performance partners endowed with artistic creation and expressive capacity. YouTube:https://youtu.be/uE8LBV7190w The name VIVA derives from the Latin root viv-, meaning “alive” and “vitality.” It also echoes the musical marking vivace, calling to mind lively, spirited renditions, while paying homage to the iconic track Viva La Vida. CADA, the “cognitive core” empowering VIVA, takes its name from the classical-music term cadenza: the virtuosic passage where performers freely unleash musical emotion. Together, VIVA × CADA embodies the Portuguese phrase Viva cada dia – “Cherish every day.” VIVA Solves the Dexterity “Impossible Triangle”: Hardware Innovation Addresses Long-Standing Industry Bottlenecks Within dexterous hand development, power, speed and dexterity have long formed a so called impossible triangle: strength often comes at the cost of speed, while greater degrees of freedom cap the output of individual actuators. MirrorMe set the human hand as its design benchmark and tackled this challenge via forward engineering. The team captured and analyzed performance data from human pianists, distilled core design specifications, then carried out theoretical modelling and topological optimisation of the mechanical architecture. The resulting motion performance approaches the physiological limits of the human hand, supporting intricate hand-shape transitions, multi-finger coordination and fine trajectory control. The breakthrough uniting all three attributes lies in the world’s first tendon-linkage hybrid transmission system. Tendon transmission relocates actuators proximally and cuts distal mass to deliver high finger speed; rigid mechanical linkages preserve structural stiffness and accurate force transfer to sustain strong fingertip output. This hybrid mechanism faithfully replicates the natural synergies of human hand joints. Every keystroke and finger lift follows motion trajectories mimicking human performers, eliminating stiff, mechanical-looking movement and yielding fluid, natural motion. Built upon this architecture, the high-performance drive system delivers joint speeds exceeding 1,000° per second, with peak fingertip force reaching 33 newtons. The hand supports rapid fingering shifts as well as powerful fortissimo strikes across the full dynamic range. Challenging techniques including fast scales, trills and repeated notes can be rendered reliably, delivering ample performance margin for tightly synchronised real-time human-robot ensemble playing. The collaborative rendition of Can-Can – a piece making extreme simultaneous demands on robotic strength, speed and fine dexterity – serves as a demonstration of how MirrorMe has cracked this classic impossible triangle. VIVA × CADA: VIVA as the Dexterous Performer, CADA as the Music Embodied Foundation Model CADA, MirrorMe’s self-developed music embodied foundation model, gives VIVA its cognitive “mind.” If VIVA constitutes the physical body that brings music to life, CADA is the brain that grants it musical intelligence. The integrated pipeline closes the full loop spanning music comprehension, composition, embodied performance and feedback-driven learning. A general foundation model first interprets natural-language prompts and musical intent. A music generation module then crafts melodies and arrangements. A performance strategy model translates abstract artistic expression into concrete fingering, touch, force and timing commands, which the VIVA dexterous hand executes on a physical piano. Crucially, each performance marks not an endpoint, but the start of a learning cycle. The system continuously captures acoustic signals, kinematics and real-world playback results, compares outputs against target references, diagnoses deviations and adjusts performance strategies. This establishes a continuous “compose–perform–perceive–evaluate–learn” loop. Rather than executing a static task once, the robot accumulates embodied experience and polishes its technique through physical interaction, rendering the same composition with increasing refinement over time. Viva la Vida: Nueva Vida, premiered at the launch event, was co-created by the foundation model in dialogue with human collaborators, then independently practised and fine-tuned by the robot to shape its own artistic interpretation. Animating Machinery: From Mechanical Motion to Musical Expression According to the team, VIVA represents far more than a piano-playing robotic hand. Hardware is inherently cold. Yet once the machine can strike keys, modulate touch force, follow melodic lines and animate music, it unlocks rich expressive possibilities. MirrorMe views music as a high-barrier scenario weaving together cognition, creativity, expression and precise manipulation—an ideal testbed for exploring deep fusion between foundation models and robotic hardware. General foundation models deliver understanding, reasoning and interactive capability; domain-specific models rapidly translate general intelligence into professional expertise; robotic actuators execute actions in the physical world; ongoing sensory feedback enables continuous skill improvement. This framework charts a key direction for the future of robotics. By starting with music comprehension and live performance, the team aims to equip robots with broader capabilities: to understand, create, act, interact and keep learning. To grant machines a body; to let cognition emerge from embodiment; and to make that cognition audible. The VIVA × CADA milestone propels robots beyond pre-scripted movement toward artistic expression, transporting artificial intelligence out of digital spaces and into our physical reality. About MirrorMe MirrorMe Technology originates from a robotics team at Zhejiang University, building on a decade of technological accumulation. The company focuses on collaborative innovation spanning original “Robot Body – Embodied Model – Ecosystem”. It has independently developed the world’s only software for full-body coupled dynamics design for robots, substantially expanding performance limits. Its full-size humanoid robot Bolt features golden human body proportions and ushers in an era where humanoid robots reach speeds of 10 m/s. MirrorMe has proposed the Distributed Embodied Intelligence Architecture (DEIA). This framework connects large language models, vertical foundational models and robot bodies to integrate cognition and motion. Its VIVA × CADA system (dexterous hand × music embodied large model) enables real-time four-hand piano duets between humans and robots for the first time. DEIA endows models with a physical body, allowing ideas to be heard, bringing the beauty of technology into daily life. Led by Dr. Jin Yongbin, a post-95s researcher, MirrorMe has been featured by major media outlets including CCTV-1, CCTV International, South Korea’s KBS and Brazil’s TV Globo. Having secured multiple rounds of financing, the company’s products are now in mass production and delivery. MirrorMe is undergoing rapid business expansion. Company:MirrorMe Technology (Shanghai) Co., Ltd Email: pr@mirrormetech.com 29/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

The Next Decade of Medical AI: How Humans and AI Collaborate – A Conversation between Kevin Kelly and Dr. Ning Song of Diagens Tech (2526. HK)

EQS via SeaPRwire.com / 28/09/2026 / 10:44 UTC+8 On 25 September, during the 5th Global Digital Trade Expo held in China, the 2026 Festival of Medical AI hosted by Diagens Technology Co., Ltd. (2526. HK, Diagens‑B, “Diagens Tech”) , themed “the Next Decade of Medical AI”, brought together Kevin Kelly, futurist and founding editor-in-chief of Wired magazine, and Dr. Ning Song, Founder and Chairman of the Board of Diagens Tech. The two discussed the industrialisation of medical AI, the future relationship between clinicians and AI, technological innovation and next-generation capabilities. The conversation centred on one core question: as AI’s adoption in healthcare becomes an established trend, the next phase hinges not merely on model performance, but also on sustainably producing medical AI, reshaping clinician-AI relations, and embedding technology into broader clinical practice. The discussion spanned the flourishing landscape of medical AI, “AI does medicine, humans do doctoring”, innovation, choice and learning in the AI era, and ultimately explored how humans, technology and industry could collaborate. I. The Next Phase of Medical AI: From Owning a Single Model to Owning Capacity for Continuous AI Creation Kevin Kelly described the integration of AI and healthcare as inevitable. In his view, AI’s entry into medicine was an irreversible trend, and Diagens Tech was among the first pursuing a holistic approach to medical diagnosis. Tasks that AI could perform faster, more reliably and more accurately would gradually be delegated to the AI. Given that AI adoption in healthcare is inevitable, the next question arose: will medical AI eventually converge into one unified “best answer”? Dr Song held the opposite view. He noted that even for the same disease, patient and medical image, interpretations might vary across hospitals, clinicians and regions. Because of this inherent diversity in medicine, Dr Song argued that the future of medical AI should not be dominated by a single solution, but instead feature a diverse ecosystem. In his vision, every specialist radiologist could train their own AI Copilot based on Diagens Tech’s self-developed iMedImage® foundational model for medical imaging. The AI assistant would absorb the clinician’s unique clinical expertise, rather than forcing everyone to rely on one generic AI system pre‑built by third parties. Kevin Kelly responded promptly that customised medical imaging and diagnostic capabilities built for individual hospitals and clinicians would be of great significance. Clinicians naturally held slightly different observational perspectives, and these nuances could be reflected in their respective AI Copilot. In Kelly’s view, software requires constant rewriting, algorithms keep evolving, and AI needs retraining in the AI era. A company’s true long-term asset, therefore, might not be a single advanced software platform or algorithm, but the process that continuously generates new software, algorithms and AI systems. This very “process” was embodied in Diagens Tech’s iMedLoop™ platform, an accelerator for medical imaging AI research and production. Centred on the iMedImage® foundation model, it links iMedStudio™, the multi-modal intelligent annotation and data generation workspace; iMedMaaS®, the model training and deployment platform; and DoctorBench®, the unified evaluation framework. It spans the full pipeline: data generation, model training, standardised evaluation, release, deployment and application feedback. This creates a medical imaging data flywheel: broader real-world deployment generates more high-quality real-world data and feedback to continuously enhance model capability. More capable models, in turn, support more specialties, tasks and clinical scenarios, generating fresh data and feedback to create a self-reinforcing cycle – the more the models are deployed, the more capable they become, and greater capability in turn fuels wider adoption. II. When AI Handles “Medicine”: Redefining Clinicians’ Value and the Boundaries of Healthcare As AI assumes a growing share of medical information processing and diagnostic tasks, how will the role of clinicians evolve? Kevin Kelly offered his verdict: “AI does medicine, humans do doctoring.” He observed that people already consult AI before seeing a clinician. Even patients with trusted doctors often seek information from AI first for its instant responses – this is not a future scenario, but an existing reality. Yet accessing medical information is never equivalent to seeing a clinician. Beyond diagnostics and knowledge, humans need empathy, wisdom, counselling, support and judgement. Patients sometimes need someone to hold their hand, guide them through treatment journeys, and encourage them to adhere to medication and health-critical behaviours. Therefore, as AI takes on more of the medicine work, clinicians gain more time to focus on doctoring. Dr Song then shifted the discussion to the next generation. For adults today, AI is an emerging technology. But the younger generation grows up in a world where AI has always been present. Will AI be seen as a natural companion? If they place greater trust in AI-generated health advice, what expectations will they hold for the humanistic care delivered by clinicians? Kelly answered with the analogy of the calculator. Today, people rarely doubt the output when using a calculator. He believed that once medical AI achieves sufficient accuracy and reliability, people might develop similar trust, and would no longer consciously question whether they can trust AI. However, he quickly added: healthcare requires more than mere accuracy. People want inspiration. We want someone to help us be better. We need psychological support to guide us through. The younger generation might trust results from medical AI, yet human needs stretch far beyond information and diagnosis. When the audience asked who stood to benefit most in the age of medical AI, Kevin Kelly replied first: “It’s ultimately the patients.” Dr Song offered a different perspective. He stated that when looking ahead over the next five to ten years, it is better to focus on the broader population rather than segment people by their roles, such as clinicians, patients or researchers. The wealthiest groups already have access to scarce, high-quality care even without AI. Where AI can deliver real impact is in boosting the efficiency and reach of limited healthcare resources, improving population-wide health outcomes. “The greatest value of this industry,” said Dr Song, “lies not in supporting a narrow group, but in benefiting a far larger, broader population – and this is what we have consistently strived to achieve.” This gave deeper context to the notion of “AI does medicine, humans do doctoring”. For Diagens Tech, foundation models and industrialised systems are ultimately about more than producing more AI systems. They aim to make scarce high-quality medical capabilities accessible to more people with greater efficiency, advancing inclusive medical AI. III. When Answers Are Easily Accessible: Judgement, Learning and Creation as Core Skills in the AI Era As AI becomes increasingly adept at generating answers, will it transform how innovation happens? Kevin Kelly’s belief is that AI will bring substantial innovation across the entire healthcare sector, particularly in medical imaging, and this shift is taking place at great speed. As AI becomes cheaper and more accessible, it will be integrated into a wider range of medical devices and applications. Yet he drew a distinction between two types of innovation. The first consists of routine innovation and incremental improvements, work that AI already performs very well. The second is breakthrough innovation, which seldom emerges from obvious answers but from unexpected, even disruptive ideas. Innovation of this kind remains challenging and still relies on humans. Kevin Kelly noted that outputs generated by AI often reflect a form of “consensus”. True innovation, however, sometimes demands that people explore ideas beyond consensus. Clinicians may acknowledge that AI’s assessment aligns with prevailing consensus, while forming alternative hypotheses and judgements based on their understanding of the individual patient. In his view, experimentation beyond consensus is where innovation can emerge. Dr Song fully agreed. When the conversation turned to the capabilities required in the AI era, Dr Song outlined three pillars: first, asking good questions; second, making decisions; third, perseverance. He emphasised the third point in particular: the capacity to persist and stay committed amid hardships and setbacks. This applies not only to young people but to everyone living in the AI age. The themes of questioning, decision-making and perseverance anchored the ensuing discussion. As barriers to knowledge fall rapidly and people gain access to ever greater volumes of information and possibilities, does choice itself become a burden? Can AI help resolve this dilemma? Kevin Kelly called this the “paradox of choice”. When options multiply beyond a certain threshold, decision-making becomes harder. Sometimes, distilling dozens of possibilities down to four makes action simpler. People already use AI for this purpose: overwhelmed by a long list of attractions, they ask AI “What should I see and do?”, and AI helps narrow down the many possibilities into a shortlist. While AI expands access to information, it also helps people streamline choices. This does not mean humans hand over the act of choosing to AI. On the contrary, as machines grow more adept at generating answers and options, humanity’s ability to ask meaningful questions, judge what is worth selecting, and take accountability for decisions becomes ever more critical. The conversation on the next decade of medical AI circled back to learning. Kevin Kelly argued that one of the most vital capabilities for the future is “learning how to learn”. Technology evolves at such a rapid pace that many skills required in the future have no established curricula as yet, making the ability to learn how to learn increasingly important. As a result, learning will increasingly take place at work. Organisations such as Diagens Tech will become more like “schools” in the future. Many skills for working alongside new AI systems are not yet covered by established university programmes, yet enterprises already need talent with these capabilities. Companies therefore take part in talent development and education. Dr Song concurred. He commented that companies constantly identify a need for such talent yet struggle to find enough graduates equipped with these skills. Hence, “Why not train them ourselves?” In September 2026, Diagens Tech and The Hong Kong Polytechnic University launched their Joint Laboratory for Artificial General Intelligence and Medical Applications, built precisely to nurture talent for the AI era. Kevin Kelly then recalled his experience at Wired during the early days of the Internet. Back then, the Internet was still nascent; there were no formal training programmes, and almost no one possessed a full set of “Internet skills”. They recruited young people and learned alongside them to build new capabilities, effectively “inventing the internet together”. Rather than prioritising existing technical skills, they valued aptitude, attitude and character. The future will bring more than a continuous stream of new models. A new generation of clinicians, engineers and young people will learn new knowledge, raise new questions, and co-create capabilities that do not exist today. AI has repeatedly proven capable of tackling increasingly sophisticated tasks. In the decade ahead, the key question may shift away from how intelligent AI can become to how humans will work with this power and what direction we choose to take it. Healthcare serves as a vital testbed. It demands technical accuracy while requiring humans to retain judgement, accountability, trust and creativity. It seeks to extend scarce specialist expertise to broader populations while preserving diversity across clinicians, patients and clinical scenarios. This is the core value of the conversation. Kevin Kelly explored the emerging new order of the AI age, while Dr Song grounded these discussions in real clinical settings and the day-to-day decisions faced by clinicians, patients and companies. For Diagens Tech, the future extends far beyond new product launches. Diagens Tech will help shape new frameworks for medical AI development and collaboration, advancing technology while engaging clinicians, engineers and young practitioners to frame new questions and build new capabilities. Where previous technological revolutions redefined how humanity accesses information and connects globally, medical AI now explores how technology can weave itself more deeply into human life, health and decision-making. Diagens Tech aims to be an active participant in this future as it takes form. 28/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Why ATGL’s Small Scale Could Become an Advantage in Enterprise AI

EQS via SeaPRwire.com / 25/09/2026 / 09:00 UTC+8 Alpha Technology Group may not need the resources of a global technology giant to create investment value. Its opportunity lies in moving faster, solving narrower business problems and turning customised AI deployments into reusable products. Anthony Tsang, president and executive director of ATGL, featured on the August 2026 cover of CAPITAL magazine. The global artificial intelligence industry is often analysed through scale. Investors tend to focus on the companies with the largest models, the most advanced semiconductor infrastructure and the greatest financial resources. That approach is understandable, but it may overlook a separate source of value emerging within enterprise AI. As artificial intelligence moves from experimentation into everyday business operations, competitive advantage may depend less on who owns the largest model and more on who can adapt AI to a specific workflow, customer environment or industry problem. This creates a different opportunity for Alpha Technology Group Limited. ATGL is unlikely to compete with the world’s largest technology companies in computing infrastructure or foundation‑model development. It may not need to. Its investment potential could instead come from its ability to operate as a focused enterprise‑AI developer—combining customised models, reusable AI agents and industry‑specific implementation. In that context, the company’s relatively small scale may become an advantage rather than simply a limitation. Enterprise AI is becoming a last‑mile problem The availability of powerful AI models does not automatically produce successful enterprise adoption. Companies still need to determine how AI will connect with existing databases, internal approval systems, customer‑service processes, security controls and regulatory requirements. A model may be technically capable, but the commercial value is created only when it becomes part of a reliable business process. This “last mile” of AI deployment is where smaller, specialised technology companies may be able to compete. Unlike a major global platform provider, ATGL can potentially concentrate on narrower customer requirements. It can modify applications for individual organisations, respond to local operating conditions and work directly with customers whose needs may be too specialised to attract the attention of larger vendors. ATGL’s historical experience in customised system development, cloud‑based IT services and AI‑powered optical character recognition gives it a practical background in implementing technology for particular customer requirements. Its new AlphaClaw strategy can therefore be interpreted not as a complete departure from the past, but as an attempt to convert that implementation experience into more reusable products. (sec.gov) This distinction is important. The company is not beginning with only an abstract AI concept. It is attempting to build a platform on top of capabilities developed through its earlier project‑based operations. Small scale can support faster product iteration Large technology companies benefit from capital, infrastructure and distribution. They can also face internal complexity, slower procurement processes and the need to support large numbers of customers through standardised products. ATGL has a different operating profile. Its smaller organisational structure may allow it to test an AI agent with a customer, revise the application and redeploy it without navigating the same layers of decision‑making that exist inside a global corporation. That flexibility could be particularly valuable during the early development of enterprise AI, when customer requirements are still changing and standard industry practices have not yet been fully established. On June 25, 2026, ATGL identified Exclusive Large Language Model solutions, AlphaClaw AI Agents and the AlphaClaw AI Agent Marketplace as its principal business activities. The company said its earlier cloud‑based IT and AI‑OCR services had been integrated into or replaced by these offerings. (sec.gov) Strategically, this gives ATGL an opportunity to transform individual customer projects into a product‑development process. An agent originally created for one customer‑service workflow could potentially be adapted for another company. A document‑processing capability developed for one industry might later become a standardised skill offered through the AlphaClaw marketplace. If this process works, every deployment could contribute not only revenue, but also reusable software components, implementation knowledge and a broader product catalogue. The resulting advantage would not come from having the largest model. It would come from shortening the distance between customer demand and product development. Vertical applications could provide an efficient route to market ATGL’s most promising commercial path may be through selected industries rather than the entire enterprise‑AI market. Vertical markets often involve specialised terminology, industry‑specific records and established operational procedures. Generic AI tools may not be sufficient for organisations that require traceability, data control and integration with existing systems. ATGL’s collaboration with Wai Yuen Tong Medicine provides an example of this approach. Announced on June 16, 2026, the project involves the development of an AI‑ and blockchain‑based traceability system for traditional Chinese medicine products. (sec.gov) The investment relevance of this initiative goes beyond one partnership. A successful traceability system could demonstrate that ATGL is capable of combining AI with industry data, product verification and specialised operational requirements. Components of the system could potentially be adapted for other fields in which authenticity, supply‑chain records or product histories are important. This is how a small technology company may create value efficiently: not by addressing every possible use case, but by developing expertise within a limited number of commercially relevant workflows. Each vertical deployment can function as a reference case. It can also produce intellectual property, customer knowledge and technical modules that reduce the effort required for future implementations. Hong Kong could serve as a commercial proving ground ATGL’s Hong Kong base may also provide an unusual strategic position. Hong Kong contains companies operating across finance, healthcare, professional services, logistics, retail and cross‑border trade. Many of these organisations manage commercially sensitive information and may prefer AI applications that offer greater control over data and deployment. ATGL has presented AlphaClaw as a customisable enterprise environment, including cloud‑based and on‑premises deployment options. If the company can establish credible applications in its home market, Hong Kong could serve as a proving ground before selected products are introduced to customers elsewhere. This possibility is reinforced by ATGL’s stated intention to explore new markets, including the United States. Its April 24, 2026 board and management appointments added experience in international business, government relations, legal affairs, corporate strategy and cross‑border market development. (sec.gov) The potential advantage is therefore not simply geographic. ATGL may be able to combine local implementation capabilities with a broader international commercial network. That could allow it to develop solutions in Hong Kong, validate them with operating customers and then adapt successful applications for other markets. This remains a strategic possibility rather than a proven expansion model. Nevertheless, it offers ATGL a more differentiated position than that of a conventional local IT contractor. AlphaMind Lab adds longer‑term technology optionality ATGL’s collaboration with the Hong Kong University of Science and Technology provides another element of potential upside. The two parties established AlphaMind Lab in March 2025 to research Alpha Engine, a proposed architecture intended to reduce dependence on extensive data collection and manual annotation when developing dedicated AI models. (sec.gov) The technical targets associated with Alpha Engine have not yet been independently demonstrated as commercial outcomes. They should therefore be treated as research objectives rather than established performance. Even so, the strategic logic is relevant. Customised AI development can be expensive because businesses must collect data, label information, train models and repeatedly test performance. If AlphaMind Lab produces technology that reduces part of this process, ATGL could potentially lower the cost and time required to develop specialised agents. That would strengthen the connection between the company’s research and commercial strategies:‑ Alpha Engine could support model development;‑ Exclusive LLM solutions could provide customised intelligence;‑ AlphaClaw agents could turn that intelligence into business applications; and‑ the marketplace could distribute successful agents and specialised skills. This structure gives ATGL several routes through which research investment might eventually create value. A low revenue base creates potential operating leverage ATGL’s historical financial position is a source of risk, but it also changes the mathematics of future growth. For the fiscal year ended September 30, 2025, the company reported approximately US467,577 in gross profit. It also recorded a net loss of approximately US$9.05 million, including significant share‑based compensation and impairment charges. (sec.gov) These results do not support the conclusion that AlphaClaw is already commercially established. However, the low historical revenue base means that a limited number of meaningful enterprise contracts could have a visible effect on the company’s future revenue mix. This is an important feature of the investment case. A large technology company may need billions of dollars in additional AI revenue to produce a material change in group performance. ATGL begins from a much smaller base. If the company secures enterprise licences, recurring subscriptions or multiple commercial deployments, the proportional impact could be considerably greater. That does not make growth inevitable. It means the financial sensitivity to successful execution may be high. The same principle applies to reusable software. Once an agent has been developed, additional customer deployments may require less engineering effort than creating each solution from the beginning. If ATGL can reuse core capabilities while limiting implementation costs, revenue could grow faster than the associated development expense. That is the potential source of operating leverage behind the AlphaClaw strategy. The marketplace is a distribution strategy The AlphaClaw AI Agent Marketplace should not be evaluated only as an online catalogue. Its more important role may be as a distribution and product‑expansion mechanism. ATGL intends to offer its own agents through the marketplace while potentially allowing third‑party developers and partners to contribute agents or specialised capabilities under revenue‑sharing arrangements. (sec.gov) If third‑party participation develops, ATGL could expand its range of applications without funding the entire development cost internally. External contributors could gain access to enterprise customers, while ATGL could earn a share of marketplace revenue and increase the value of its broader platform. This model could create a positive cycle: More agents would make the platform more useful to customers. More customers would make the platform more attractive to developers. More developers would broaden the range of industries the platform can serve. A broader product range could support additional customer adoption. The marketplace is still at an early stage, and there is not yet sufficient public evidence of this network effect. Nevertheless, its inclusion gives ATGL a growth mechanism that extends beyond the capacity of its internal development team. A positive investment case built on optionality The constructive case for ATGL is not that the company has already become a mature AI platform. It is that several elements of a potentially scalable business are beginning to connect:‑ experience in customised enterprise technology;‑ a defined AI‑agent product strategy;‑ research support through AlphaMind Lab;‑ an industry‑specific commercial use case;‑ potential cloud and on‑premises deployment;‑ a marketplace capable of supporting external participation; and‑ an expanded international management network. Individually, none of these elements proves commercial success. Together, however, they give ATGL multiple ways to create value. A successful customer project can become a reusable agent. A reusable agent can be distributed through the marketplace. Research can potentially reduce development costs. Vertical applications can create reference cases. International relationships can open additional channels to market. This interconnected structure is what makes the company strategically more interesting than its historical financial results alone might suggest. Investment conclusion ATGL’s small scale creates undeniable financial and execution risks. It also gives the company a degree of strategic flexibility that larger competitors may find difficult to reproduce. The company can focus on specialised problems, work closely with individual customers and adapt its products without protecting a large legacy software business. Its low revenue base also means that successful enterprise deployments could materially change its financial profile. The positive investment thesis is therefore not based on ATGL defeating global technology giants at their own game. It is based on the possibility that ATGL can compete differently. By combining customised AI, vertical‑market knowledge, reusable agents and marketplace distribution, the company may be able to occupy the space between general‑purpose AI models and the specialised systems enterprises actually need. If ATGL can convert that position into repeat deployments, the company’s current size may prove to be more than a limitation. It may become the source of its greatest strategic advantage. Investor takeaway ATGL’s opportunity may not depend on scale at the foundation‑model level. Its potential advantage lies in speed, customisation and vertical execution. Because the company begins from a relatively low revenue base, even a limited number of successful and reusable enterprise deployments could materially alter its growth profile—provided that management controls development costs and converts projects into recurring platform revenue. 25/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Shenwan Hongyuan Initiates Envision Green (01783) at Buy: Dual-Business Transformation Inflection Point Established, Fair Valuation of HK$25.827 Billion, Implies 94.7% Upside from Current Market Cap

EQS via SeaPRwire.com / 24/09/2026 / 11:29 UTC+8 According to the Zhitong Finance APP,Shenwan Hongyuan said in a research note that Envision Green (01783) has completed its transformation from a traditional construction contractor into a dual-business platform spanning circular economy and AI compute. U.S. industrial metal reverse recycling provides highly visible cash flow, with telecom carriers’ copper network decommissioning offering a steady supply of feedstock, fixed-price contracts locking in costs, and elevated metal prices widening spreads. Hong Kong power battery recycling secures scarce capacity through the city’s first licensed processing facility, with retired battery volumes poised to surge; a dual model of service fees and resource recovery offers both stability and upside. The acquisition of YV Cloud marks its entry into AI compute leasing, where booming industry demand is combining with rising energy-consumption and licensing barriers on the supply side; performance thresholds and deferred payment mechanisms provide downside protection for the premium acquisition. With the three businesses progressing in sequence, the earnings growth path is clear. The broker believes the combined fair value of the company’s resource recycling and AI compute services businesses could reach HK$25.827 billion, implying 94.7% upside to its current market capitalization of HK$13.262 billion. It initiated coverage with a “Buy” rating. Key takeaways: Transformation inflection point established: circular economy as the foundation; AI compute as a new growth engine. Envision Green’s predecessor was founded in 1985 and initially focused on Hong Kong construction engineering. Since 2022, the company has moved into second-life power battery utilization and recycling and U.S. reverse supply chain management through M&A. As high-margin circular economy revenue increased, the company reported net profit attributable to shareholders of HK$61 million in FY2025/26, its first positive result since the business transformation. In June 2026, it moved to acquire YV CLOUD Limited and Shanghai Yovole Cloud Computing, entering AIDC and AI compute services and building a multi-business model spanning infrastructure engineering, resource recycling and compute leasing. Resource recycling: solid core business with clear growth prospects. U.S. copper cable decommissioning is accelerating, and reverse recycling demand is entering a sustained release phase. Telecom giants such as AT&T and Verizon are accelerating their migration to wireless and fiber networks, an irreversible trend. The company has deep ties with leading customers including AT&T, Verizon and Amazon, leaving ample room to increase penetration among existing clients. It uses fixed-term contracts to lock in procurement costs at agreed prices and sells high-purity copper and aluminum recovered from dismantling at market prices. With copper prices elevated, metal price gains directly widen recycling spreads, offering both earnings stability and upside. Power battery recycling: retired battery volumes are set to surge; scarce licences build a moat. As of end-May 2026, Hong Kong had about 178,000 EVs, nearly 10 times the 2020 level. With private cars set to be fully electric by 2035, the fleet could exceed 500,000 units. Rising battery numbers will create substantial retired battery recycling demand, with volumes expected to accelerate from 2026. The Basel Convention Ban Amendment prohibits, in principle, the export of hazardous waste to non-OECD regions such as mainland China and Southeast Asia, making local compliant capacity highly scarce. The company’s Tuen Mun EcoPark plant is Hong Kong’s first power battery processing facility. In June 2026, it obtained a chemical waste disposal licence from the Hong Kong Environmental Protection Department and began production that month, with designed annual capacity of 10,000 tonnes. It is currently ramping up capacity ahead of the peak in power battery retirements. While processing service fees provide stable revenue, black mass resource recovery sales add further upside and continue to contribute incremental earnings. AI compute services: YV Cloud acquisition marks entry into AI compute, creating a new growth curve. China’s intelligent computing capacity has grown rapidly in recent years. Major internet companies have significantly increased capex in computing power, and the AIGC sector is booming. In June 2026, the company began acquiring YV CLOUD Limited and its operating company Shanghai Yovole Cloud Computing, formally entering the compute services market. As one of China’s earliest NVIDIA Cloud Partners, the target has advantages in GPU allocation priority and favorable original manufacturer pricing. Envision Green has also begun expanding its compute assets and has completed the procurement of more than 500 Nvidia high-performance GPU servers. It expects the expansion of computing capacity to inject new momentum for rapid growth. Earnings forecast and valuation: The broker forecasts revenue of HK$7.068 billion, HK$10.044 billion and HK$12.333 billion for FY2026/27–FY2028/29; net profit attributable to shareholders of HK$389 million, HK$715 million and HK$1.036 billion; EPS of HK$0.13, HK$0.24 and HK$0.34 per share; and P/E of 34x, 19x and 13x, respectively. Given the significant differences between the resource recycling and AI compute services business models, the broker uses a sum-of-the-parts valuation. As the resource recycling business’s earnings stability improves after rapid capacity ramp-up from FY2028/29, and the compute business has moved past its incubation phase, valuing the company on that fiscal year’s performance better reflects its intrinsic value. The broker estimates that in FY2028/29, resource recycling will contribute about HK$579 million in net profit attributable to shareholders. Applying a 13x P/E gives a market capitalization of HK$7.524 billion. AI compute services will contribute about HK$458 million. Applying a 40x P/E gives a market capitalization of HK$18.303 billion. The combined fair value is HK$25.827 billion, implying 94.7% upside to the current market capitalization. It initiated coverage with a “Buy” rating. 24/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Strategic alliance in Japan

EQS via SeaPRwire.com / 24/09/2026 / 04:50 MSK Solidcore Resources plc (“Solidcore” or the “Company”) is pleased to announce that it has formed a strategic exploration alliance (the “Alliance”) with Japan Gold Corp. (“Japan Gold”) covering five of its exploration project areas (the “Target Areas”) where the Company has committed to fund a three-year exploration program for a total amount of CAD$ 35 million (US$ 25 million), with the right to earn up to an 80% direct interest in the Target Areas over several development stages. In connection with the Alliance, Solidcore has acquired 78,775,000 Units of Japan Gold in a private placement, for a total consideration of CAD$ 9.45 million (US$ 6.85 million) (the “Private Placement”). Solidcore now owns 18.81% of Japan Gold’s issued and outstanding Common Shares on a non-diluted basis, and 19.9% on a partially diluted basis. “Solidcore has a long record of investing across the mining sector and of building durable partnerships, and Japan Gold’s licence portfolio stands out to us. It has the makings of a large-scale, generational gold district with a distinctive style of geology that we have been historically successfully working with, in a stable, well-regulated, developed and notably under-explored jurisdiction. We are keen to support Japan Gold’s exploration effort and to leverage development opportunities in Japan together,” said Vitaly Nesis, CEO of Solidcore Resources plc. John Proust, Chairman and Chief Executive Officer of Japan Gold Corp., said, “We are delighted to announce the alliance with Solidcore, a focused and motivated technical and financial partner with a long-term growth strategy and a leading position in the gold industry. The vision of Solidcore’s management and shareholders, of reserve growth through expanded geographic diversification is perfectly timed with Japan Gold’s extensive formative work over the past decade as the first mover in Japan. We have assembled a highly prospective and strategically important portfolio in one of the world’s best yet underexplored gold jurisdictions. The Alliance with Solidcore creates a meaningful opportunity to leverage our technical and operational expertise across district-scale targets in Japan”. Mr. Proust added, “We are aligned with Solidcore in our strategic vision, and we look forward to advancing multiple projects through committed, well-funded, staged exploration programs designed to identify significant long-term value.” STRATEGIC ALLIANCE AND STAGED EARN-IN Solidcore and Japan Gold have formed the Alliance, focused on the Target Areas in Hokkaido and Kyushu (see below) in close proximity to past producing mines, and progressed in two phases. A joint technical committee, comprising two representatives of each party and chaired by a Solidcore nominee with a tie-breaking vote, will oversee exploration budgets and work programs. Phase 1. Solidcore will fully fund a committed three-year exploration program on the Target Areas with a total budget of US$ 25 million. Following completion of the committed Phase 1 program, Solidcore will have earned a 49% direct interest in one or more of the Target Areas at its own discretion depending on exploration results. Phase 2. Conditional upon fulfilment of the Phase 1 commitments, Solidcore will have the right, at its sole discretion and on a project-by-project basis, to increase its interest in any Target Area to 70% by funding a pre-feasibility study on that Target Area within three years after the completion of the Phase 1 earn-in, and further to 80% by funding a bankable feasibility study on that Target Area within three years following delivery of the pre-feasibility study. Solidcore will have the right to become the lead coordinator of the Phase 2 program. Following the completion of a bankable feasibility study on a Target Area, Japan Gold will have the right to: sole fund its remaining interest to production on that Target Area, or dispose of one half of its remaining interest to Solidcore at a price based on the net present value of the applicable project and applying a price to net asset value (P/NAV) consistent with the P/NAV’s then applying in the market for acquisitions of similar-stage gold mining projects and convert the remaining half of that interest into a 1% net smelter return royalty, or dispose of its entire remaining interest at a price based on the net present value of the applicable project and applying a price to net asset value (P/NAV) consistent with the P/NAV’s then applying in the market for acquisitions of similar-stage gold mining projects. PRIVATE PLACEMENT Under the Private Placement, Solidcore subscribed for 78,775,000 units of Japan Gold (each, a “Unit”) at a subscription price of CAD$ 0.12 per Unit (US$ 0.087), for gross proceeds of CAD$ 9,453,000 (US$ 6.85 million). Each Unit consists of one common share (each, a “Common Share”) of Japan Gold and 0.0724 of a Common Share purchase warrant (each full warrant, a “Warrant”) for a total of 5,703,310 Warrants. The Common Shares comprised in the Units give Solidcore an 18.81% interest in Japan Gold on a non-diluted basis, before any exercise of the Warrants. Each whole Warrant entitles Solidcore to purchase one additional Common Share at an exercise price of CAD$ 0.135 for a period of three years entitling Solidcore to hold a 19.9% interest in Japan Gold on a partially diluted basis (assuming the exercise in full of the warrants held by Solidcore only, in accordance with their terms). The equity financing will allow Japan Gold to continue to conduct exploration work focused on the balance of its 22 other projects, create enhanced drilling capacity and fund general working capital. Pursuant to an investor rights agreement entered into between Solidcore and Japan Gold in connection with the Private Placement, Solidcore has the right to nominate two directors to Japan Gold’s Board of Directors for so long as it maintains an ownership interest of at least 18% of the issued and outstanding Japan Gold Common Shares on a non-diluted basis, and the right to nominate one director for so long as Solidcore maintains an ownership interest of less than 18% but at least 10% of the issued and outstanding Common Shares on a non-diluted basis, in each case subject to stock exchange and statutory eligibility requirements. Solidcore will also benefit from pro rata participation rights in future security issuances of Japan Gold in order to maintain its then-current pro rata ownership interest. At the formation of the Alliance two Solidcore’s representatives were appointed to the Japan Gold’s Board of Directors: Mr. Victor Flores and Ms. Tania Tchedaeva. Victor Flores, an advisor to Solidcore, is a highly accomplished mining and investment professional with over 35 years of experience in the precious metals sector. His career combines deep geological and exploration expertise with a strong track record in mine development, operational optimization, and capital markets. He was previously a Director of the Company. Tania Tchedaeva has served as Executive Vice President, Compliance and Corporate Governance, and Company Secretary for Solidcore Resources plc since 2011. STRATEGIC ALLIANCE TARGET AREAS[1] Hakuryu Hakuryu lies at the southern end of the Konomai epithermal gold district in northern Hokkaido. The Konomai Mine, Japan’s third-largest past-producing gold mine, produced 2.35 Moz at 6.4 g/t between 1915 and 1973. Initial drilling intersected narrow intervals of high-grade gold mineralisation within a largely untested structural zone. Bajo Bajo is located in Middle Kyushu and centres on the historic Bajo Mine, which produced 421 Koz of gold. The Sakuru-Hi vein accounted for 317 Koz at 125.9 g/t gold and 557 g/t silver. Exploration targets include southwestern extensions of the Bajo veins and the West Mineralized Zone (WMZ). A recent geophysical survey identified anomalies interpreted as potential extensions and sub-parallel features, with interpreted strike lengths exceeding 1 km. Mizobe Mizobe occupies the western edge of the Kagoshima Graben in southern Kyushu’s Hokusatsu Region. Its geological setting resembles that of Hishikari, a 13 Moz deposit, which produced approximately 9 Moz of gold between 1985-2025. Ryuo Ryuo, within the Ikutahara prospect district in northeast Hokkaido, contains five historic working areas: Jinja, Shouei, Taisei, Ryuei and Buryu. These workings followed an open-ended, 1 km zone of alteration and mineralisation before the government ordered closure in 1943 Aibetsu Aibetsu lies in northern Hokkaido’s Kamikawa district, within the Kitami mining region, and encompasses five historical gold-silver and mercury mines or mineral occurrences. Tokusei mine within the target area produced 39 Koz of gold and 473 Koz of silver from quartz-adularia veins between 1930 and 1942. Subsequent exploration included mapping, soil sampling, resistivity surveys and drilling. JAPAN GOLD Japan Gold Corp. (TSXV: JG) (OTCQB: JGLDF) is a Canadian-based and is the largest exploration company in Japan, with a portfolio of more than 3,000 sq. km of prospective mineral rights covering regions known for gold mineralization and a history of high-grade epithermal gold production. Japan offers a compelling combination of highly prospective yet underexplored geology, well-developed infrastructure, and a stable mining jurisdiction. Over the past decade, Japan Gold's leadership team, including geologists, drillers, and technical advisors, have built deep technical capabilities and unmatched in-country expertise. Their extensive experience in exploration and operations, combined with a proven track record of discoveries worldwide, positions the company as a leading explorer in the country. As a project generator, Japan Gold focuses on acquiring and advancing high quality exploration projects, with the goal of generating exploration upside for joint venture partners, providing long term upside for shareholders while minimizing dilution. More information about Japan Gold and its projects is available on the company’s website: https://japangold.com/. About Solidcore Solidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project (Ertis POX) in Kazakhstan. Enquiries Investor Relations Media Kirill Kuznetsov Alina Assanova +7 7172 47 66 55 (Kazakhstan) ir@solidcore-resources.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@solidcore-resources.kz FORWARD-LOOKING STATEMENTS This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. [1] Based on the publicly available Japan Gold information. 24/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

SAINT BELLA Marks First Anniversary at Waldorf Astoria Monarch Beach

EQS via SeaPRwire.com / 23/09/2026 / 10:19 UTC+8 The anniversary event highlighted the brand's mother-centered, all-in-one approach to postpartum care. DANA POINT, Calif., Sept. 23, 2026 - SAINT BELLA, a global luxury brand offering all-in-one postpartum care services, celebrated its first anniversary at Waldorf Astoria Monarch Beach Resort & Club with a curated event for expectant mothers. Dr. Judy Wei, an OB-GYN with nearly 20 years of experience, joined the event and shared professional insights on postpartum recovery, encouraging women to explore effective care options for a smoother, healthier recovery. The event theme, HER JOURNEY BEGINS - Welcome Aboard SAINT BELLA, honors the profound transition into motherhood. It underscores the time women need to recover, adjust, and prioritize self-care as they embrace their new roles. Guests attended a prenatal yoga session and an open conversation about pregnancy, postpartum recovery, and the support women need before and after birth. SAINT BELLA's philosophy is built around a simple idea: postpartum support should begin with the mother. All too often, after birth, much of the attention shifts to the baby, leaving mothers to manage physical recovery, sleep loss, nutrition, and the learning curve of caring for a newborn at the same time. SAINT BELLA seamlessly integrates these needs into one comprehensive program, from bespoke postpartum recovery care and overnight newborn support, to practical parenting education and chef-prepared postpartum meals designed to nourish recovery. By managing these services as one experience, SAINT BELLA reduces the burden on families to coordinate multiple providers and gives mothers more time to rest and recover. Rooted in the Eastern tradition of dedicated postpartum care and elevated through contemporary maternal wellness, professional care standards and luxury hospitality, SAINT BELLA has brought its approach to families across China, Singapore, Thailand and the United States, through both hospitality-based settings and private in-home care."At SAINT BELLA, we’ve always been on the side of women," said Minee Lin, the co-founder of SAINT BELLA. Entering its second year at Waldorf Astoria Monarch Beach, SAINT BELLA aims to expand its integrated postpartum care model to more families across the United States. The brand extends its deepest gratitude to the mothers, families, guests, and partners who have supported this location since its opening. Loving you is loving life. About SAINT BELLA SAINT BELLA is the world’s largest postpartum care center operator by revenue. As of June 2026, the Group operated 148 locations worldwide and had served more than 100,000 families. Its presence spans China, Singapore, Thailand and the United States. In the U.S., SAINT BELLA has opened three locations at Baccarat Hotel & Residences New York, Waldorf Astoria Monarch Beach Resort & Club, and The Resort at Pelican Hill. Media Contact pr@saintbella.com 23/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

From IT Services to Enterprise AI: What ATGL Must Prove Next

EQS via SeaPRwire.com / 23/09/2026 / 09:00 UTC+8 AlphaClaw gives the Nasdaq‑listed technology company a clearer platform strategy, but customer adoption, recurring revenue and capital discipline will determine whether the transition creates lasting value. (Anthony Tsang, president and executive director of ATGL, featured on the August 2026 cover of CAPITAL magazine.) The enterprise artificial intelligence market is moving beyond the initial excitement surrounding general‑purpose large language models. For investors, the more important question is now whether AI companies can turn technical capabilities into secure, repeatable and economically viable business applications. That shift provides the broader context for Alpha Technology Group Limited’s latest strategic repositioning. The Nasdaq‑listed Hong Kong technology company announced on June 25, 2026 that its principal business activities would focus on Exclusive Large Language Model solutions, AlphaClaw AI Agents and the AlphaClaw AI Agent Marketplace. The announcement represents a move away from ATGL’s historical identity as a provider of project‑based IT development, cloud services and AI‑powered optical character recognition solutions. (sec.gov) The strategy is commercially relevant. However, its investment significance will depend less on the language of AI innovation and more on the company’s ability to establish measurable adoption, recurring revenue and a defensible market position. A more focused enterprise‑AI proposition AlphaClaw consists of two connected offerings. The first is a suite of AI agents designed to support enterprise functions including customer service, human resources, sales and document processing. According to ATGL, most of the underlying skills are built using the company’s own Exclusive LLM technology and can be adapted to specific customer requirements. The second is the AlphaClaw AI Agent Marketplace, through which ATGL intends to distribute its own agents and potentially host agents or specialised skills developed by third‑party providers under revenue‑sharing arrangements. (sec.gov) Together, these offerings give ATGL a more coherent commercial structure than a conventional project‑based IT services model. Custom software projects generally depend on individual contracts, engineering capacity and one‑time implementation revenue. An agent platform, by contrast, could potentially generate a combination of deployment fees, subscriptions, usage‑based revenue and marketplace commissions. That distinction is important—but it remains a strategic possibility rather than a demonstrated financial outcome. For the marketplace model to become meaningful, ATGL will need more than a catalogue of internally developed tools. It will need active enterprise customers, credible third‑party contributors, reliable quality controls and enough transaction volume to create a functioning commercial ecosystem. The opportunity lies in applied AI ATGL does not need to compete directly with the world’s largest foundation‑model developers to build a viable business. Its more realistic opportunity may lie in applied enterprise AI: adapting models to specific workflows, integrating them with existing systems and providing organisations with greater control over data, security and operational processes. This approach could be particularly relevant to companies and public‑sector organisations that want to deploy AI without relying entirely on generic consumer‑facing platforms. ATGL describes AlphaClaw as a secure and customisable environment intended for commercial applications, although investors will ultimately need customer deployments and performance data to evaluate those claims. (sec.gov) The company’s industry collaborations may offer early indications of how that strategy could be applied. On June 16, 2026, ATGL announced a partnership with Wai Yuen Tong Medicine to develop an AI‑ and blockchain‑based traceability system for traditional Chinese medicine. The project illustrates a potential vertical use case combining data management, product verification and industry‑specific technology. (sec.gov) ATGL has also previously established AlphaMind Lab with the Hong Kong University of Science and Technology to conduct research into more efficient development of dedicated AI models. While research partnerships can support technical credibility, their commercial value will depend on whether the resulting intellectual property produces deployable products, customer contracts or licensing opportunities. (sec.gov) Commercial evidence is now the central question For institutional investors, product descriptions alone will not be sufficient. The next stage of the ATGL investment case will depend on measurable operating indicators, including:‑ the number of paying AlphaClaw customers;‑ the distinction between pilot projects and full commercial deployments;‑ contract values and revenue‑recognition schedules;‑ subscription or usage‑based revenue;‑ customer retention and expansion;‑ gross margins associated with AI deployments;‑ marketplace participation by third‑party developers; and‑ the cost of acquiring and supporting enterprise customers. These indicators would allow investors to distinguish between a promising technology concept and a scalable commercial platform. Until such data are disclosed, AlphaClaw should be viewed as an early‑stage strategic platform rather than an established growth engine. The financial starting point remains challenging ATGL’s historical financial results underline the scale of the transition. For the fiscal year ended September 30, 2025, the company reported revenue of approximately US$950,541, a decline of 40.13% from the prior fiscal year. Gross profit fell to approximately US$467,577. ATGL also reported a net loss of approximately US$9.05 million, although that figure included approximately US$5.56 million in share-based compensation and approximately US$1.74 million in impairment charges related to goodwill and intangible assets. (sec.gov) These results mainly reflect the company’s historical operations and pre-date the formal positioning of AlphaClaw as a principal business activity. They therefore do not provide a complete measure of the new strategy’s potential. At the same time, they establish a demanding baseline. The AI transition will need to produce not only revenue growth, but also an improvement in revenue quality, operating efficiency and cash generation. As of September 30, 2025, ATGL held approximately US$3.97 million in cash and cash equivalents and reported approximately US$1.69 million of net cash used in operating activities during the fiscal year. The company stated that its available financial resources were expected to meet anticipated cash needs for at least 12 months from the date of its annual report. (sec.gov) Investors should consequently monitor development expenditure, hiring, customer-acquisition costs and any future debt or equity financing. A platform strategy can offer greater scalability, but building the platform, supporting enterprise customers and attracting external developers can also require sustained investment before meaningful recurring revenue emerges. A credible strategy that now requires validation ATGL’s strategic repositioning reflects a broader change in the AI industry. The initial competition to build increasingly powerful models is being followed by a commercial race to deploy AI inside real business processes. Companies that can combine specialised models, workflow integration, data protection and reliable enterprise support may be able to capture value without competing directly with the largest global technology platforms. AlphaClaw gives ATGL a clearer position within that market. The combination of proprietary agents, customisable enterprise applications and a curated marketplace offers a more scalable narrative than the company’s historical project‑based services. But a clearer narrative is not the same as a proven business model. For professional investors, the most important signals will be customer adoption, recurring revenue, gross‑margin development, cash discipline and evidence that ATGL’s partnerships and strategic initiatives contribute directly to commercial growth. The company has now defined the direction of its transformation. The next task is to demonstrate that the technology can produce repeatable business outcomes. Investor takeaway ATGL has established a more focused enterprise‑AI strategy through AlphaClaw, but the investment case will depend on whether the company can convert its technology, partnerships and platform ambitions into disclosed customer adoption, recurring revenue and sustainable cash generation. 23/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Vaccine makers seek closer global cooperation at Beijing meeting

EQS via SeaPRwire.com / 22/09/2026 / 17:44 UTC+8 Vaccine manufacturers, global health organizations and regulators gathered in Beijing for talks aimed at strengthening cooperation across vaccine research, production and supply, as countries seek more resilient systems to respond to routine and emerging disease threats, on Tuesday, Sept. 22, 2026, Beijing time. Representatives of more than 40 vaccine manufacturers from 17 countries, including nine companies from China, are attending the 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN). The three-day meeting at the China World Hotel brings together vaccine producers, researchers, international organizations, development institutions and public health authorities. Participants include representatives from the World Health Organization, UNICEF, Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, the Gates Foundation and the World Bank Group. This year’s theme, “Transforming Innovation into immunisation,” centers on how scientific advances can be translated into vaccines that meet public health needs, can be produced at scale and can reach the populations that need them. The agenda covers cooperation in vaccine research, technology transfer, manufacturing, regulation and international procurement. Delegates are also discussing pathways to WHO prequalification, the use of artificial intelligence in vaccine development and production, public confidence in vaccination and the development of sustainable vaccine markets. DCVMN Chief Executive Officer Rajinder Kumar Suri said the meeting offered manufacturers an opportunity to build long-term relationships with global health institutions, development partners and other members of the vaccine industry. “In Beijing, we are moving beyond the familiar to explore genuinely new approaches to how vaccines are financed, developed, produced and delivered, and to ensure that the voices of manufacturers in developing countries help shape the future of immunisation,” Suri said. Manufacturers in developing countries are playing an increasingly important role in global vaccine supply, particularly in providing affordable vaccines for routine immunisation programs. Their further integration into international supply systems will depend on sustained cooperation in technology access, regulatory alignment, quality management and procurement. DCVMN seeks to support that process by representing manufacturers in international discussions and connecting them with global health organizations and industry partners. China’s experience in building vaccine research, manufacturing and disease-control capacity was among the examples discussed at the meeting. An official from China’s National Disease Control and Prevention Administration said producing a vaccine was only the first step toward reducing the burden of infectious diseases, and that innovation must ultimately be translated into broad, well-regulated immunisation programs that respond to public health needs. China has developed a broad-based vaccine research and production system capable of serving both domestic immunisation programs and overseas markets. According to the official, nine vaccine products from China have obtained WHO prequalification and entered international procurement and supply systems, while vaccines produced in the country are used in disease-prevention programs across Asia, Africa and Latin America. China has also remained polio-free, eliminated neonatal tetanus and been certified malaria-free by the WHO. Beijing officials said the city would continue to support international cooperation in vaccine research, manufacturing and professional training. The Chinese capital is home to numerous universities, research institutes, hospitals and biopharmaceutical companies, while industrial clusters such as the Daxing biomedical industry base help translate research into products and manufacturing capacity. A dedicated session at the meeting will examine how these resources can be linked more closely with public health priorities and international partnerships. The meeting comes as governments and global health organizations seek to diversify vaccine production and make supply chains more resilient to future health emergencies. Discussions in Beijing have also focused on forms of cooperation that go beyond the transfer of individual products or technologies, with longer-term partnerships aimed at strengthening local capabilities in research, regulation, manufacturing and workforce development. DCVMN describes its annual meeting as a forum where manufacturers can present their priorities directly to global health organizations, development partners and national institutions, while gaining a clearer understanding of international standards and procurement requirements. The meeting runs through Sept. 24. About DCVMN Founded in 2000, the Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary, public health-oriented, non-profit international organisation of vaccine manufacturers from developing countries, with its international secretariat based in Switzerland. Spanning 17 countries, the network brings together more than 40 manufacturers who contribute more than 60% of global vaccine production and supply vaccines to over 170 countries. DCVMN members have met up to 70% of the vaccine demand of Africa, PAHO and Gavi 5.0. Guided by its motto "We connect to protect", DCVMN promotes the sustained supply of and equitable access to quality, affordable vaccines through capacity building, professional training and technical exchanges. For more information, visit dcvmn.org. Media Contact: info@dcvmn.net 22/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Yip’s Chemical Subsidiary “Sino-Hypro” Debuts at ICIF 2026 with Milligram-Level Oil and Gas Recovery Technology

EQS via SeaPRwire.com / 22/09/2026 / 12:45 UTC+8 Facilitating Pollution Reduction, Carbon Emission Cuts, and Efficiency Gains for the Chemical Industry via "Zero Incineration, Zero Carbon Emission" Pure Physical Recovery Technology (Hong Kong, 22 September 2026) Beijing Sino-Hypro Petrochemical Tech. Co., Ltd. (北京信諾海博石化科技發展有限公司) ("Sino-Hypro"), a chemical gas separation and recovery enterprise under Yip's Chemical Holdings Limited (SEHK: 00408) ("Yip's Chemical" or the "Company", together with its subsidiaries collectively referred to as the "Group"), was invited to attend the 23rd International Chemical Industry Fair (ICIF 2026) held last week at the Shanghai New International Expo Centre. Against the regulatory backdrop of the opening year of the "15th Five-Year Plan" and the implementation of the Ecological Environment Code, Sino-Hypro showcased its self-developed "milligram-level (mg-level) oil and gas recovery technology". Centered on pure physical recovery, the technology ensures mg-level compliance for tail gas emissions without creating additional carbon emissions, becoming a major highlight among domestic and international industry stakeholders at the exhibition. Self-Developed Customised Processes Break Free from Traditional Incineration Limits, Demonstrating Outstanding Environmental and Economic Synergies As a National High-Tech Enterprise, Sino-Hypro has focused on the R&D and application of industrial organic gas separation and recovery technologies since its founding in 2008. The company operates an equipment manufacturing plant and R&D center in Qingdao, Shandong, holding over 30 invention patents. Managing volatile organic compound (VOCs) emissions during the production, storage, and transportation of oil and chemical products has long been an industry pain point. Given the wide variety of VOCs, dispersed emission sources, and differing site conditions, there is no one-size-fits-all recovery process. Confronted with increasingly stringent domestic environmental standards, Sino-Hypro did not settle for the shortcut of simple technology introduction. Instead, grounded in fundamental chemical engineering theory and continuous iterations through self-developed engineering experiments, the company delivers customised solutions tailored to specific gas characteristics and site conditions. Breaking away from traditional simple incineration models, Sino-Hypro adheres to a self-developed "pure physical recovery" route, offering advantages that extend far beyond emission reduction: Safety and Compliance: The process operates entirely at ambient temperatures, eliminating deflagration risks and aligning with the petrochemical industry's strict anti-explosion and open-flame standards. Flexibility and Efficiency: The equipment footprint is compact and free from safety distance constraints, allowing for flexible site selection. Resource Recycling: Centered on adsorption separation, organic matter in the oil gas is efficiently adsorbed and liquefied into reusable resources, achieving "source-to-source recycling and in-situ recovery". While ensuring milligram-level tail gas emissions compliance, it generates substantial economic value for enterprises. Mr. Zhang Guorui (張國瑞on the right of the picture above), Founder and Chief Engineer of Sino-Hypro, graduated from East China Petroleum Institute (now China University of Petroleum) in 1982. As a Senior Engineer in Petrochemical Processes, he served as Chief Engineer at PetroChina Urumqi Petrochemical Engineering Institute for over two decades. He stated: "We have successfully deployed over 140 sets of equipment that have stably achieved milligram-level tail gas concentration standards. The essence of oil and gas recovery is to efficiently recover organic matter in liquid form, allowing compliant tail gas to be discharged directly into the atmosphere. Our technology generally achieves an organic substance recovery rate of over 99.95%. Taking a 10,000 m³/h crude oil recovery unit at a major domestic port as an example, while recovering 5 tonnes of crude oil per hour, it directly reduces carbon emissions by 15 tonnes per hour compared to traditional incineration methods. Our latest R&D technology reduces non-methane total hydrocarbon concentrations in tail gas below 60 mg/m³ and benzene series compounds below 2 mg/m³, demonstrating outstanding environmental and economic synergies. This provides the petrochemical industry with a Chinese solution that achieves 'zero incineration, zero carbon emission, and waste-gas-to-resource transformation'. Mr. Hu Xiaopeng (胡小鹏on the left of the picture above), General Manager of Sino-Hypro, pointed out: "With the deepened implementation of policies such as the VOC Environmental Protection Tax, procurement logic among major petrochemical clients is undergoing a profound shift. It is upgrading from merely pursuing 'tail gas emission compliance' to meticulously calculating the 'three accounts': direct financial returns from recovered oil and gas, VOC environmental tax reductions, and reduced carbon compliance pressure through resource recycling." To date, Sino-Hypro’s service footprint extensively covers domestic petrochemical giants such as PetroChina, Sinopec, and Wanhua Chemical, while successfully entering Shell’s supply chain system. Sino-Hypro guarantees a 10-year adsorbent lifespan directly in its contracts, and all deployed installations operate stably, earning high acclaim from clients. Mr. Hu emphasised: "When large clients purchase an oil and gas recovery system, they are not buying a simple machine, but a complete system solution capable of operating reliably and continuously for ten years. All economic returns are built on the foundation of long-term, stable, mg-level compliance." This capability for sustained compliance serves as Sino-Hypro’s core moat to maintain high gross margins amid low-price competition in the industry. Yip’s Chemical Strategic Restructuring Reshapes Business Portfolio and Profit Quality With a 55-year history since its founding in 1971, Yip’s Chemical has faced global market volatility and intensified domestic industry competition in recent years. The Group has adopted strategic portfolio optimisation as its core transformation strategy, proactively scaling down low-barrier businesses with intense market competition, concentrating resources on core strengths, and reallocating capital into high-tech emerging businesses to enhance overall risk resistance and profit quality. Last month, the Group announced its 2026 interim results, reporting a significant year-on-year increase of 113.5% in profit attributable to owners to HK$141 million, with overall gross margin increasing by 2.1 percentage points year-on-year to 26.9%. Mr. Ip Kwan, Francis (fourth from the left in the front row of the picture above), Chief Executive Officer of Yip’s Chemical, stated: "Deeply cultivated the chemical industry for over half a century, Yip’s Chemical holds deep passion and operational expertise in the sector. Therefore, our transformation remains steadfastly anchored in the chemical core, while setting two mandatory criteria for project selection: first, it must deliver environmental benefits; second, it must possess high technological content. At the end of 2025, the Group successfully acquired an approximately 60% equity in Sino-Hypro, officially entering the field of 'Chemical Gas Separation and Recovery'. This new business aligns seamlessly with national 'Dual Carbon' strategies and environmental policy directions, marking a pivotal milestone in the Group’s transition toward a high-tech, high-value-added specialty chemical enterprise. Since completing the acquisition, we have supported Sino-Hypro across multiple dimensions, including client resources, supply chain, talent, and management systems. The Group’s management will continue to collaborate closely with the founding shareholders to leverage Sino-Hypro’s strong technical foundation alongside Yip’s Chemical’s operational experience and resource network to deepen synergies. I firmly believe Sino-Hypro will continue to unlock strong commercial potential." Mr. Ip continued: "Looking ahead, the Group will adopt 'a leading development platform for chemical businesses' as its core strategic positioning. While consolidating its existing core businesses such as coatings and inks, the Group will leverage its financial strengths of low gearing and robust cash flow. Through a dual-driven strategy of 'in-house incubation' and 'active acquisitions', we will nurture emerging businesses and proactively seek high-quality M&A targets. Furthermore, the Group has established a dedicated team to actively capture market opportunities, targeting environmental protection and new energy industrial projects as key strategic priorities to drive high-quality and sustainable development." - End - About Yip’s Chemical Holdings Limited (Incorporated in the Cayman Islands with limited liability) Founded in 1971 and listed on the Hong Kong Stock Exchange (SEHK: 00408) since 1991, Yip’s Chemical has been dedicated to the chemical industry for more than half a century. The Group’s long-term vision is to become “a leading development platform for chemical businesses” driven by green, innovative technology, professional services and highly respected brands that enrich people’s lives. The Group’s core businesses include inks, industrial and architectural coatings, specialty resins, lubricants and chemical gas separation and recovery. The core businesses have established leading positions in China in their respective sectors. “Bauhinia Variegata” is the largest inks manufacturer in China; “Hang Cheung” coatings holds a leading position in China’s high-end plastic coatings segment; Bauhinia Advanced Materials Group also operates well-known brands including “Bauhinia” and “Camel” paints as well as “Da Chang” polymers; “Hercules” and “Pacoil” lubricants rank among the market leaders; “Sino-Hypro” is recognised as a leading enterprise in chemical gas separation and recovery in China. The Group is also a core investor in “Handsome Chemical”, the world’s largest acetate solvents producer. Leveraging its stable shareholder structure, extensive nationwide manufacturing and sales network, and a dynamic portfolio of strong brands, the Group has built a robust foundation in the domestic chemical industry. Going forward, the Group will drive sustainable innovation in chemical operations and accelerate the development of a more scalable and resilient platform. Learn more about Yip’s Chemical on: www.yipschemical.com Media and Investor Enquiries Yip’s Chemical Holdings LimitedMs. Wing So Tel:(852) 2675 2385 Email:wing.so@yipschemical.com DLK Advisory Limited Ms. Michelle Shi Tel: (852) 2854 8711 Email: michelleshi@dlkadvisory.com Ms. Kathleen Mui Tel: (852) 2854 8727 Email: kathleenmui@dlkadvisory.com 22/09/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More